2src › Citations

Crystal structures of c-Src reveal features of its autoinhibitory mechanism.

Xu W, Doshi A, Lei M, Eck MJ, Harrison SC
Mol Cell 3 629-38 (1999)
Cited: 621 times
EuropePMC logo PMID: 10360179

Abstract

Src family kinases are maintained in an assembled, inactive conformation by intramolecular interactions of their SH2 and SH3 domains. Full catalytic activity requires release of these restraints as well as phosphorylation of Tyr-416 in the activation loop. In previous structures of inactive Src kinases, Tyr-416 and flanking residues are disordered. We report here four additional c-Src structures in which this segment adopts an ordered but inhibitory conformation. The ordered activation loop forms an alpha helix that stabilizes the inactive conformation of the kinase domain, blocks the peptide substrate-binding site, and prevents Tyr-416 phosphorylation. Disassembly of the regulatory domains, induced by SH2 or SH3 ligands, or by dephosphorylation of Tyr-527, could lead to exposure and phosphorylation of Tyr-416.

Reviews - 2src mentioned but not cited (19)

  1. Structure and dynamic regulation of Src-family kinases. Engen JR, Wales TE, Hochrein JM, Meyn MA, Banu Ozkan S, Bahar I, Smithgall TE. Cell Mol Life Sci 65 3058-3073 (2008)
  2. Dynamics-Driven Allostery in Protein Kinases. Kornev AP, Taylor SS. Trends Biochem Sci 40 628-647 (2015)
  3. Markov state models provide insights into dynamic modulation of protein function. Shukla D, Hernández CX, Weber JK, Pande VS. Acc Chem Res 48 414-422 (2015)
  4. Mechanisms of drug resistance in kinases. Barouch-Bentov R, Sauer K. Expert Opin Investig Drugs 20 153-208 (2011)
  5. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. Nussinov R, Jang H, Tsai CJ, Cheng F. PLoS Comput Biol 15 e1006658 (2019)
  6. The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases. Shah NH, Amacher JF, Nocka LM, Kuriyan J. Crit Rev Biochem Mol Biol 53 535-563 (2018)
  7. Understanding and exploiting substrate recognition by protein kinases. Turk BE. Curr Opin Chem Biol 12 4-10 (2008)
  8. Redox regulation of tyrosine kinase signalling: more than meets the eye. Dustin CM, Heppner DE, Lin MJ, van der Vliet A. J Biochem 167 151-163 (2020)
  9. The Fyn-ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells. Gerbec ZJ, Thakar MS, Malarkannan S. Front Immunol 6 472 (2015)
  10. Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes. Staudt RP, Alvarado JJ, Emert-Sedlak LA, Shi H, Shu ST, Wales TE, Engen JR, Smithgall TE. J Biol Chem 295 15158-15171 (2020)
  11. Targeting protein kinases with selective and semipromiscuous covalent inhibitors. Miller RM, Taunton J. Methods Enzymol 548 93-116 (2014)
  12. Dynamic regulatory features of the protein tyrosine kinases. Amatya N, Lin DY, Andreotti AH. Biochem Soc Trans 47 1101-1116 (2019)
  13. Exploiting holistic approaches to model specificity in protein phosphorylation. Palmeri A, Ferrè F, Helmer-Citterich M. Front Genet 5 315 (2014)
  14. Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors. Jha V, Macchia M, Tuccinardi T, Poli G. Cancers (Basel) 12 E2327 (2020)
  15. New targets for HIV drug discovery. Puhl AC, Garzino Demo A, Makarov VA, Ekins S. Drug Discov Today 24 1139-1147 (2019)
  16. Structural insights into redox-active cysteine residues of the Src family kinases. Heppner DE. Redox Biol 41 101934 (2021)
  17. Chapter 4. Predicting and characterizing protein functions through matching geometric and evolutionary patterns of binding surfaces. Liang J, Tseng YY, Dundas J, Binkowski TA, Joachimiak A, Ouyang Z, Adamian L. Adv Protein Chem Struct Biol 75 107-141 (2008)
  18. Regulatory Roles of the N-Terminal Intrinsically Disordered Region of Modular Src. Kato G. Int J Mol Sci 23 2241 (2022)
  19. Metabolic protein kinase signalling in neuroblastoma. Smiles WJ, Catalano L, Stefan VE, Weber DD, Kofler B. Mol Metab 75 101771 (2023)

Articles - 2src mentioned but not cited (160)

  1. Benchmarking sets for molecular docking. Huang N, Shoichet BK, Irwin JJ. J Med Chem 49 6789-6801 (2006)
  2. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Kornev AP, Haste NM, Taylor SS, Eyck LF. Proc Natl Acad Sci U S A 103 17783-17788 (2006)
  3. Proteome-wide covalent ligand discovery in native biological systems. Backus KM, Correia BE, Lum KM, Forli S, Horning BD, González-Páez GE, Chatterjee S, Lanning BR, Teijaro JR, Olson AJ, Wolan DW, Cravatt BF. Nature 534 570-574 (2016)
  4. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Nat Struct Mol Biol 15 1109-1118 (2008)
  5. Recognition of functional sites in protein structures. Shulman-Peleg A, Nussinov R, Wolfson HJ. J Mol Biol 339 607-633 (2004)
  6. Activation pathway of Src kinase reveals intermediate states as targets for drug design. Shukla D, Meng Y, Roux B, Pande VS. Nat Commun 5 3397 (2014)
  7. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Nat Commun 4 1403 (2013)
  8. Structural basis for the recognition of c-Src by its inactivator Csk. Levinson NM, Seeliger MA, Cole PA, Kuriyan J. Cell 134 124-134 (2008)
  9. Molecular docking screens using comparative models of proteins. Fan H, Irwin JJ, Webb BM, Klebe G, Shoichet BK, Sali A. J Chem Inf Model 49 2512-2527 (2009)
  10. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Marcotte DJ, Liu YT, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E, Jenkins TJ, Romanowski MJ, Baker DP, Silvian LF. Protein Sci 19 429-439 (2010)
  11. Thr38 and Ser198 are Pto autophosphorylation sites required for the AvrPto-Pto-mediated hypersensitive response. Sessa G, D'Ascenzo M, Martin GB. EMBO J 19 2257-2269 (2000)
  12. From residue coevolution to protein conformational ensembles and functional dynamics. Sutto L, Marsili S, Valencia A, Gervasio FL. Proc Natl Acad Sci U S A 112 13567-13572 (2015)
  13. Evaluation of DOCK 6 as a pose generation and database enrichment tool. Brozell SR, Mukherjee S, Balius TE, Roe DR, Case DA, Rizzo RC. J Comput Aided Mol Des 26 749-773 (2012)
  14. Generalized Scalable Multiple Copy Algorithms for Molecular Dynamics Simulations in NAMD. Jiang W, Phillips JC, Huang L, Fajer M, Meng Y, Gumbart JC, Luo Y, Schulten K, Roux B. Comput Phys Commun 185 908-916 (2014)
  15. A dynamically coupled allosteric network underlies binding cooperativity in Src kinase. Foda ZH, Shan Y, Kim ET, Shaw DE, Seeliger MA. Nat Commun 6 5939 (2015)
  16. Pharmit: interactive exploration of chemical space. Sunseri J, Koes DR. Nucleic Acids Res 44 W442-8 (2016)
  17. A multi-template combination algorithm for protein comparative modeling. Cheng J. BMC Struct Biol 8 18 (2008)
  18. Bioorthogonal Chemical Activation of Kinases in Living Systems. Zhang G, Li J, Xie R, Fan X, Liu Y, Zheng S, Ge Y, Chen PR. ACS Cent Sci 2 325-331 (2016)
  19. Letter Atomistic view of the conformational activation of Src kinase using the string method with swarms-of-trajectories. Gan W, Yang S, Roux B. Biophys J 97 L8-L10 (2009)
  20. Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker. Yan Q, Barros T, Visperas PR, Deindl S, Kadlecek TA, Weiss A, Kuriyan J. Mol Cell Biol 33 2188-2201 (2013)
  21. On the molecular discrimination between adenine and guanine by proteins. Nobeli I, Laskowski RA, Valdar WS, Thornton JM. Nucleic Acids Res 29 4294-4309 (2001)
  22. Structure, regulation, signaling, and targeting of abl kinases in cancer. Hantschel O. Genes Cancer 3 436-446 (2012)
  23. Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. Meng Y, Roux B. J Mol Biol 426 423-435 (2014)
  24. Src kinase activation: A switched electrostatic network. Ozkirimli E, Post CB. Protein Sci 15 1051-1062 (2006)
  25. Direct cysteine sulfenylation drives activation of the Src kinase. Heppner DE, Dustin CM, Liao C, Hristova M, Veith C, Little AC, Ahlers BA, White SL, Deng B, Lam YW, Li J, van der Vliet A. Nat Commun 9 4522 (2018)
  26. From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. Kuhn D, Weskamp N, Schmitt S, Hüllermeier E, Klebe G. J Mol Biol 359 1023-1044 (2006)
  27. Global distribution of conformational states derived from redundant models in the PDB points to non-uniqueness of the protein structure. Burra PV, Zhang Y, Godzik A, Stec B. Proc Natl Acad Sci U S A 106 10505-10510 (2009)
  28. An electrostatic network and long-range regulation of Src kinases. Ozkirimli E, Yadav SS, Miller WT, Post CB. Protein Sci 17 1871-1880 (2008)
  29. Folding free energy function selects native-like protein sequences in the core but not on the surface. Jaramillo A, Wernisch L, Héry S, Wodak SJ. Proc Natl Acad Sci U S A 99 13554-13559 (2002)
  30. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. Gushwa NN, Kang S, Chen J, Taunton J. J Am Chem Soc 134 20214-20217 (2012)
  31. Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding. Liu T, Altman RB. PLoS Comput Biol 7 e1002326 (2011)
  32. Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate. Wang Q, Vogan EM, Nocka LM, Rosen CE, Zorn JA, Harrison SC, Kuriyan J. Elife 4 (2015)
  33. Optimal assignment methods for ligand-based virtual screening. Jahn A, Hinselmann G, Fechner N, Zell A. J Cheminform 1 14 (2009)
  34. Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology. Zhang C, Lopez MS, Dar AC, Ladow E, Finkbeiner S, Yun CH, Eck MJ, Shokat KM. ACS Chem Biol 8 1931-1938 (2013)
  35. Tyrosine Kinase Activation and Conformational Flexibility: Lessons from Src-Family Tyrosine Kinases. Meng Y, Pond MP, Roux B. Acc Chem Res 50 1193-1201 (2017)
  36. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases. Meng Y, Lin YL, Roux B. J Phys Chem B 119 1443-1456 (2015)
  37. Transition path theory analysis of c-Src kinase activation. Meng Y, Shukla D, Pande VS, Roux B. Proc Natl Acad Sci U S A 113 9193-9198 (2016)
  38. Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. Lovera S, Morando M, Pucheta-Martinez E, Martinez-Torrecuadrada JL, Saladino G, Gervasio FL. PLoS Comput Biol 11 e1004578 (2015)
  39. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. Georghiou G, Kleiner RE, Pulkoski-Gross M, Liu DR, Seeliger MA. Nat Chem Biol 8 366-374 (2012)
  40. Interaction with the Src homology (SH3-SH2) region of the Src-family kinase Hck structures the HIV-1 Nef dimer for kinase activation and effector recruitment. Alvarado JJ, Tarafdar S, Yeh JI, Smithgall TE. J Biol Chem 289 28539-28553 (2014)
  41. Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases. Banavali NK, Roux B. Proteins 74 378-389 (2009)
  42. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Tong M, Pelton JG, Gill ML, Zhang W, Picart F, Seeliger MA. Nat Commun 8 2160 (2017)
  43. Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. Zhao J, Zhang Y, Ithychanda SS, Tu Y, Chen K, Qin J, Wu C. J Biol Chem 284 34308-34320 (2009)
  44. Integration of signaling in the kinome: Architecture and regulation of the αC Helix. Taylor SS, Shaw AS, Kannan N, Kornev AP. Biochim Biophys Acta 1854 1567-1574 (2015)
  45. Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains. Zhou HX. Biophys J 91 3170-3181 (2006)
  46. Protein structure prediction provides comparable performance to crystallographic structures in docking-based virtual screening. Du H, Brender JR, Zhang J, Zhang Y. Methods 71 77-84 (2015)
  47. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Sci Rep 5 14538 (2015)
  48. A Combined Approach Reveals a Regulatory Mechanism Coupling Src's Kinase Activity, Localization, and Phosphotransferase-Independent Functions. Ahler E, Register AC, Chakraborty S, Fang L, Dieter EM, Sitko KA, Vidadala RSR, Trevillian BM, Golkowski M, Gelman H, Stephany JJ, Rubin AF, Merritt EA, Fowler DM, Maly DJ. Mol Cell 74 393-408.e20 (2019)
  49. Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. Alvarado JJ, Betts L, Moroco JA, Smithgall TE, Yeh JI. J Biol Chem 285 35455-35461 (2010)
  50. SplitPocket: identification of protein functional surfaces and characterization of their spatial patterns. Tseng YY, Dupree C, Chen ZJ, Li WH. Nucleic Acids Res 37 W384-9 (2009)
  51. The Activation of c-Src Tyrosine Kinase: Conformational Transition Pathway and Free Energy Landscape. Fajer M, Meng Y, Roux B. J Phys Chem B 121 3352-3363 (2017)
  52. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. Cell Rep 25 449-463.e4 (2018)
  53. An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase. Pucheta-Martínez E, Saladino G, Morando MA, Martinez-Torrecuadrada J, Lelli M, Sutto L, D'Amelio N, Gervasio FL. Sci Rep 6 24235 (2016)
  54. Differential sensitivity of Src-family kinases to activation by SH3 domain displacement. Moroco JA, Craigo JK, Iacob RE, Wales TE, Engen JR, Smithgall TE. PLoS One 9 e105629 (2014)
  55. Microtubule-mediated Src tyrosine kinase trafficking in neuronal growth cones. Wu B, Decourt B, Zabidi MA, Wuethrich LT, Kim WH, Zhou Z, MacIsaac K, Suter DM. Mol Biol Cell 19 4611-4627 (2008)
  56. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. Hari SB, Perera BG, Ranjitkar P, Seeliger MA, Maly DJ. ACS Chem Biol 8 2734-2743 (2013)
  57. Structural analysis of Staphylococcus aureus serine/threonine kinase PknB. Rakette S, Donat S, Ohlsen K, Stehle T. PLoS One 7 e39136 (2012)
  58. Methods for SAXS-based structure determination of biomolecular complexes. Yang S. Adv Mater 26 7902-7910 (2014)
  59. Structure of WbdD: a bifunctional kinase and methyltransferase that regulates the chain length of the O antigen in Escherichia coli O9a. Hagelueken G, Huang H, Clarke BR, Lebl T, Whitfield C, Naismith JH. Mol Microbiol 86 730-742 (2012)
  60. c-Src binds to the cancer drug Ruxolitinib with an active conformation. Duan Y, Chen L, Chen Y, Fan XG. PLoS One 9 e106225 (2014)
  61. miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13. Xu S, Wang T, Yang Z, Li Y, Li W, Wang T, Wang S, Jia L, Zhang S, Li S. Oncotarget 7 45687-45701 (2016)
  62. Brought to life: targeted activation of enzyme function with small molecules. Bishop AC, Chen VL. J Chem Biol 2 1-9 (2009)
  63. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors. Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y, Lin L, Zhu W, Ding J, Jiang H, Liu H. Eur J Med Chem 44 1982-1988 (2009)
  64. Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors. Leonard SE, Register AC, Krishnamurty R, Brighty GJ, Maly DJ. ACS Chem Biol 9 1894-1905 (2014)
  65. SH2-catalytic domain linker heterogeneity influences allosteric coupling across the SFK family. Register AC, Leonard SE, Maly DJ. Biochemistry 53 6910-6923 (2014)
  66. Application of 3D Zernike descriptors to shape-based ligand similarity searching. Venkatraman V, Chakravarthy PR, Kihara D. J Cheminform 1 19 (2009)
  67. Cheminformatics meets molecular mechanics: a combined application of knowledge-based pose scoring and physical force field-based hit scoring functions improves the accuracy of structure-based virtual screening. Hsieh JH, Yin S, Wang XS, Liu S, Dokholyan NV, Tropsha A. J Chem Inf Model 52 16-28 (2012)
  68. Conformational rearrangements upon Syk auto-phosphorylation. Arias-Palomo E, Recuero-Checa MA, Bustelo XR, Llorca O. Biochim Biophys Acta 1794 1211-1217 (2009)
  69. Cysteine residues 244 and 458-459 within the catalytic subunit of Na,K-ATPase control the enzyme's hydrolytic and signaling function under hypoxic conditions. Petrushanko IY, Mitkevich VA, Lakunina VA, Anashkina AA, Spirin PV, Rubtsov PM, Prassolov VS, Bogdanov NB, Hänggi P, Fuller W, Makarov AA, Bogdanova A. Redox Biol 13 310-319 (2017)
  70. Identification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target. Chiba S, Ikeda K, Ishida T, Gromiha MM, Taguchi YH, Iwadate M, Umeyama H, Hsin KY, Kitano H, Yamamoto K, Sugaya N, Kato K, Okuno T, Chikenji G, Mochizuki M, Yasuo N, Yoshino R, Yanagisawa K, Ban T, Teramoto R, Ramakrishnan C, Thangakani AM, Velmurugan D, Prathipati P, Ito J, Tsuchiya Y, Mizuguchi K, Honma T, Hirokawa T, Akiyama Y, Sekijima M. Sci Rep 5 17209 (2015)
  71. The Tyrosine Kinase c-Src Specifically Binds to the Active Integrin αIIbβ3 to Initiate Outside-in Signaling in Platelets. Wu Y, Span LM, Nygren P, Zhu H, Moore DT, Cheng H, Roder H, DeGrado WF, Bennett JS. J Biol Chem 290 15825-15834 (2015)
  72. Kincore: a web resource for structural classification of protein kinases and their inhibitors. Modi V, Dunbrack RL. Nucleic Acids Res 50 D654-D664 (2022)
  73. c-Yes tyrosine kinase is a potent suppressor of ES cell differentiation and antagonizes the actions of its closest phylogenetic relative, c-Src. Zhang X, Meyn MA, Smithgall TE. ACS Chem Biol 9 139-146 (2014)
  74. Hsp90 dependence of a kinase is determined by its conformational landscape. Luo Q, Boczek EE, Wang Q, Buchner J, Kaila VR. Sci Rep 7 43996 (2017)
  75. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. Temps C, Lietha D, Webb ER, Li XF, Dawson JC, Muir M, Macleod KG, Valero T, Munro AF, Contreras-Montoya R, Luque-Ortega JR, Fraser C, Beetham H, Schoenherr C, Lopalco M, Arends MJ, Frame MC, Qian BZ, Brunton VG, Carragher NO, Unciti-Broceta A. Cancer Res 81 5438-5450 (2021)
  76. Structure determination of high-energy states in a dynamic protein ensemble. Stiller JB, Otten R, Häussinger D, Rieder PS, Theobald DL, Kern D. Nature 603 528-535 (2022)
  77. An iterative compound screening contest method for identifying target protein inhibitors using the tyrosine-protein kinase Yes. Chiba S, Ishida T, Ikeda K, Mochizuki M, Teramoto R, Taguchi YH, Iwadate M, Umeyama H, Ramakrishnan C, Thangakani AM, Velmurugan D, Gromiha MM, Okuno T, Kato K, Minami S, Chikenji G, Suzuki SD, Yanagisawa K, Shin WH, Kihara D, Yamamoto KZ, Moriwaki Y, Yasuo N, Yoshino R, Zozulya S, Borysko P, Stavniichuk R, Honma T, Hirokawa T, Akiyama Y, Sekijima M. Sci Rep 7 12038 (2017)
  78. MotifAnalyzer-PDZ: A computational program to investigate the evolution of PDZ-binding target specificity. Valgardson J, Cosbey R, Houser P, Rupp M, Van Bronkhorst R, Lee M, Jagodzinski F, Amacher JF. Protein Sci 28 2127-2143 (2019)
  79. Remodeling of HIV-1 Nef Structure by Src-Family Kinase Binding. Moroco JA, Alvarado JJ, Staudt RP, Shi H, Wales TE, Smithgall TE, Engen JR. J Mol Biol 430 310-321 (2018)
  80. RhoA GTPase phosphorylated at tyrosine 42 by src kinase binds to β-catenin and contributes transcriptional regulation of vimentin upon Wnt3A. Kim JG, Mahmud S, Min JK, Lee YB, Kim H, Kang DC, Park HS, Seong J, Park JB. Redox Biol 40 101842 (2021)
  81. Separating distinct structures of multiple macromolecular assemblies from cryo-EM projections. Verbeke EJ, Zhou Y, Horton AP, Mallam AL, Taylor DW, Marcotte EM. J Struct Biol 209 107416 (2020)
  82. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction. Fahrenkamp D, de Leur HS, Küster A, Chatain N, Müller-Newen G. Cell Commun Signal 13 10 (2015)
  83. The generality of kinase-catalyzed biotinylation. Senevirathne C, Embogama DM, Anthony TA, Fouda AE, Pflum MK. Bioorg Med Chem 24 12-19 (2016)
  84. Distal loop flexibility of a regulatory domain modulates dynamics and activity of C-terminal SRC kinase (csk). Barkho S, Pierce LC, McGlone ML, Li S, Woods VL, Walker RC, Adams JA, Jennings PA. PLoS Comput Biol 9 e1003188 (2013)
  85. Enrichment of chemical libraries docked to protein conformational ensembles and application to aldehyde dehydrogenase 2. Wang B, Buchman CD, Li L, Hurley TD, Meroueh SO. J Chem Inf Model 54 2105-2116 (2014)
  86. Identification of Druggable Kinase Target Conformations Using Markov Model Metastable States Analysis of apo-Abl. Paul F, Meng Y, Roux B. J Chem Theory Comput 16 1896-1912 (2020)
  87. New approaches to high-throughput structure characterization of SH3 complexes: the example of Myosin-3 and Myosin-5 SH3 domains from S. cerevisiae. Musi V, Birdsall B, Fernandez-Ballester G, Guerrini R, Salvatori S, Serrano L, Pastore A. Protein Sci 15 795-807 (2006)
  88. Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases. Chakraborty S, Inukai T, Fang L, Golkowski M, Maly DJ. ACS Chem Biol 14 1249-1259 (2019)
  89. Letter A selective NMR probe to monitor the conformational transition from inactive to active kinase. Xie Q, Fulton DB, Andreotti AH. ACS Chem Biol 10 262-268 (2015)
  90. Heat dissipation guides activation in signaling proteins. Weber JK, Shukla D, Pande VS. Proc Natl Acad Sci U S A 112 10377-10382 (2015)
  91. Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery. Taylor SS, Kaila-Sharma P, Weng JH, Aoto P, Schmidt SH, Knapp S, Mathea S, Herberg FW. Front Mol Neurosci 13 538219 (2020)
  92. Remarkably Stereospecific Utilization of ATP α,β-Halomethylene Analogues by Protein Kinases. Ni F, Kung A, Duan Y, Shah V, Amador CD, Guo M, Fan X, Chen L, Chen Y, McKenna CE, Zhang C. J Am Chem Soc 139 7701-7704 (2017)
  93. A switch in nucleotide affinity governs activation of the Src and Tec family kinases. von Raußendorf F, de Ruiter A, Leonard TA. Sci Rep 7 17405 (2017)
  94. Analysis of the impact of solvent on contacts prediction in proteins. Samsonov SA, Teyra J, Anders G, Pisabarro MT. BMC Struct Biol 9 22 (2009)
  95. Bioinformatic search of plant microtubule-and cell cycle related serine-threonine protein kinases. Karpov PA, Nadezhdina ES, Yemets AI, Matusov VG, Nyporko AY, Shashina NY, Blume YB. BMC Genomics 11 Suppl 1 S14 (2010)
  96. Extensive Reliability Evaluation of Docking-Based Target-Fishing Strategies. Lapillo M, Tuccinardi T, Martinelli A, Macchia M, Giordano A, Poli G. Int J Mol Sci 20 E1023 (2019)
  97. Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods. Wong YH, Lin CL, Chen TS, Chen CA, Jiang PS, Lai YH, Chu L, Li CW, Chen JJ, Chen BS. BMC Med Genomics 8 Suppl 4 S4 (2015)
  98. PatchSurfers: Two methods for local molecular property-based binding ligand prediction. Shin WH, Bures MG, Kihara D. Methods 93 41-50 (2016)
  99. Polymodal allosteric regulation of Type 1 Serine/Threonine Kinase Receptors via a conserved electrostatic lock. Botello-Smith WM, Alsamarah A, Chatterjee P, Xie C, Lacroix JJ, Hao J, Luo Y. PLoS Comput Biol 13 e1005711 (2017)
  100. Visualizing protein breathing motions associated with aromatic ring flipping. Mariño Pérez L, Ielasi FS, Bessa LM, Maurin D, Kragelj J, Blackledge M, Salvi N, Bouvignies G, Palencia A, Jensen MR. Nature 602 695-700 (2022)
  101. 5'-β,γ-CHF-ATP diastereomers: synthesis and fluorine-mediated selective binding by c-Src protein kinase. Hwang CS, Kung A, Kashemirov BA, Zhang C, McKenna CE. Org Lett 17 1624-1627 (2015)
  102. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region. Moroco JA, Baumgartner MP, Rust HL, Choi HG, Hur W, Gray NS, Camacho CJ, Smithgall TE. Chem Biol Drug Des 86 144-155 (2015)
  103. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). Wang L, Ferrao R, Li Q, Hatcher JM, Choi HG, Buhrlage SJ, Gray NS, Wu H. J Biol Chem 294 4511-4519 (2019)
  104. Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor. Lee HJ, Pham PC, Pei H, Lim B, Hyun SY, Baek B, Kim B, Kim Y, Kim MH, Kang NW, Min HY, Kim DD, Lee J, Lee HY. Theranostics 11 1918-1936 (2021)
  105. Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase. Taskinen B, Ferrada E, Fowler DM. J Biol Chem 292 18518-18529 (2017)
  106. Ensembler: Enabling High-Throughput Molecular Simulations at the Superfamily Scale. Parton DL, Grinaway PB, Hanson SM, Beauchamp KA, Chodera JD. PLoS Comput Biol 12 e1004728 (2016)
  107. Introducing novel potent anticancer agents of 1H-benzo[f]chromene scaffolds, targeting c-Src kinase enzyme with MDA-MB-231 cell line anti-invasion effect. Ahmed HEA, El-Nassag MAA, Hassan AH, Okasha RM, Ihmaid S, Fouda AM, Afifi TH, Aljuhani A, El-Agrody AM. J Enzyme Inhib Med Chem 33 1074-1088 (2018)
  108. Paralog-Specific Patterns of Structural Disorder and Phosphorylation in the Vertebrate SH3-SH2-Tyrosine Kinase Protein Family. Dos Santos HG, Siltberg-Liberles J. Genome Biol Evol 8 2806-2825 (2016)
  109. Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. Chhikara BS, Ashraf S, Mozaffari S, St Jeans N, Mandal D, Tiwari RK, Ul-Haq Z, Parang K. Molecules 25 E2135 (2020)
  110. A computational protocol to evaluate the effects of protein mutants in the kinase gatekeeper position on the binding of ATP substrate analogues. Romano V, de Beer TA, Schwede T. BMC Res Notes 10 104 (2017)
  111. All-atom adaptively biased path optimization of Src kinase conformational inactivation: Switched electrostatic network in the concerted motion of αC helix and the activation loop. Wu H, Huang H, Post CB. J Chem Phys 153 175101 (2020)
  112. Comparison of protein structures by growing neighborhood alignments. Bhattacharya S, Bhattacharyya C, Chandra NR. BMC Bioinformatics 8 77 (2007)
  113. Conformational transition paths harbor structures useful for aiding drug discovery and understanding enzymatic mechanisms in protein kinases. Wong CF. Protein Sci 25 192-203 (2016)
  114. Control of genetically prescribed protein tyrosine kinase activities by environment-linked redox reactions. Nakashima I, Kawamoto Y, Takeda K, Kato M. Enzyme Res 2011 896567 (2011)
  115. Cyclic Peptides as Protein Kinase Inhibitors: Structure-Activity Relationship and Molecular Modeling. Sanner MF, Zoghebi K, Hanna S, Mozaffari S, Rahighi S, Tiwari RK, Parang K. J Chem Inf Model 61 3015-3026 (2021)
  116. Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Liu WS, Wang RR, Yue H, Zheng ZH, Lu XH, Wang SQ, Dong WL, Wang RL. J Biomol Struct Dyn 38 3814-3824 (2020)
  117. Evaluating the dynamics and electrostatic interactions of folded proteins in implicit solvents. Hua DP, Huang H, Roy A, Post CB. Protein Sci 25 204-218 (2016)
  118. Kinase Activation by Small Conformational Changes. Lopez ED, Burastero O, Arcon JP, Defelipe LA, Ahn NG, Marti MA, Turjanski AG. J Chem Inf Model 60 821-832 (2020)
  119. Molecular basis for the interaction between human choline kinase alpha and the SH3 domain of the c-Src tyrosine kinase. Kall SL, Whitlatch K, Smithgall TE, Lavie A. Sci Rep 9 17121 (2019)
  120. Network approach of the conformational change of c-Src, a tyrosine kinase, by molecular dynamics simulation. Yoon HJ, Lee S, Park SJ, Wu S. Sci Rep 8 5673 (2018)
  121. Selective Proteolysis to Study the Global Conformation and Regulatory Mechanisms of c-Src Kinase. Agius MP, Ko KS, Johnson TK, Kwarcinski FE, Phadke S, Lachacz EJ, Soellner MB. ACS Chem Biol 14 1556-1563 (2019)
  122. Structural insights into the intertwined dimer of fyn SH2. Huculeci R, Garcia-Pino A, Buts L, Lenaerts T, van Nuland N. Protein Sci 24 1964-1978 (2015)
  123. Expression and purification of Src-family kinases for solution NMR studies. Piserchio A, Cowburn D, Ghose R. Methods Mol Biol 831 111-131 (2012)
  124. Importance of consensus region of multiple-ligand templates in a virtual screening method. Okuno T, Kato K, Minami S, Terada TP, Sasai M, Chikenji G. Biophys Physicobiol 13 149-156 (2016)
  125. N-terminus-independent activation of c-Src via binding to a tetraspan(in) TM4SF5 in hepatocellular carcinoma is abolished by the TM4SF5 C-terminal peptide application. Song HE, Lee Y, Kim E, Cho CY, Jung O, Lee D, Lee EG, Nam SH, Kang M, Macalino SJY, Kim JE, Jung JW, Kwon SW, Choi S, Lee JW. Theranostics 11 8092-8111 (2021)
  126. Parallel Chemoselective Profiling for Mapping Protein Structure. Potter ZE, Lau HT, Chakraborty S, Fang L, Guttman M, Ong SE, Fowler DM, Maly DJ. Cell Chem Biol 27 1084-1096.e4 (2020)
  127. Reciprocally coupled residues crucial for protein kinase Pak2 activity calculated by statistical coupling analysis. Hsu YH, Traugh JA. PLoS One 5 e9455 (2010)
  128. Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative. Chakraborty MP, Bhattacharyya S, Roy S, Bhattacharya I, Das R, Mukherjee A. J Biol Chem 296 100449 (2021)
  129. Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis. Mao J, Zhu K, Long Z, Zhang H, Xiao B, Xi W, Wang Y, Huang J, Liu J, Shi X, Jiang H, Lu T, Wen Y, Zhang N, Meng Q, Zhou H, Ruan Z, Wang J, Luo C, Xi X. Adv Sci (Weinh) 9 e2103228 (2022)
  130. An aggregate analysis of many predicted structures to reduce errors in protein structure comparison caused by conformational flexibility. Godshall BG, Tang Y, Yang W, Chen BY. BMC Struct Biol 13 Suppl 1 S10 (2013)
  131. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain. Johnson TK, Soellner MB. Bioconjug Chem 27 1745-1749 (2016)
  132. Mechanical force can enhance c-Src kinase activity by impairing autoinhibition. Daday C, de Buhr S, Mercadante D, Gräter F. Biophys J 121 684-691 (2022)
  133. Na,K-ATPase Acts as a Beta-Amyloid Receptor Triggering Src Kinase Activation. Petrushanko IY, Tverskoi AM, Barykin EP, Petrovskaya AV, Strelkova MA, Leonova OG, Anashkina AA, Tolstova AP, Adzhubei AA, Bogdanova AY, Makarov AA, Mitkevich VA. Cells 11 2753 (2022)
  134. Projections for fast protein structure retrieval. Bhattacharya S, Bhattacharyya C, Chandra NR. BMC Bioinformatics 7 Suppl 5 S5 (2006)
  135. Recruitment of rare 3-grams at functional sites: is this a mechanism for increasing enzyme specificity? Tobi D, Bahar I. BMC Bioinformatics 8 226 (2007)
  136. Structural analysis of receptor-like kinase SOBIR1 reveals mechanisms that regulate its phosphorylation-dependent activation. Wei X, Wang Y, Zhang S, Gu T, Steinmetz G, Yu H, Guo G, Liu X, Fan S, Wang F, Gu Y, Xin F. Plant Commun 3 100301 (2022)
  137. Structural and functional characterization of the divergent Entamoeba Src using Src inhibitor-1. López-Contreras L, Hernández-Ramírez VI, Herrera-Martínez M, Montaño S, Constantino-Jonapa LA, Chávez-Munguía B, Talamás-Rohana P. Parasit Vectors 10 500 (2017)
  138. Structural insights into the recognition of β3 integrin cytoplasmic tail by the SH3 domain of Src kinase. Katyal P, Puthenveetil R, Vinogradova O. Protein Sci 22 1358-1365 (2013)
  139. Use of QSAR Global Models and Molecular Docking for Developing New Inhibitors of c-src Tyrosine Kinase. Ancuceanu R, Tamba B, Stoicescu CS, Dinu M. Int J Mol Sci 21 E19 (2019)
  140. Chemically reprogramming the phospho-transfer reaction to crosslink protein kinases to their substrates. Wong AW, Urisman A, Burlingame AL, Shokat KM. Protein Sci 28 654-662 (2019)
  141. Editorial Covalent drugs targeting histidine - an unexploited opportunity? Che J, Jones LH. RSC Med Chem 13 1121-1126 (2022)
  142. Evaluating the therapeutic role of selected active compounds in Plumula Nelumbinis on pulmonary hypertension via network pharmacology and experimental analysis. Xiao X, Luo F, Fu M, Jiang Y, Liu S, Liu B. Front Pharmacol 13 977921 (2022)
  143. Virtual screening of specific insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National Cancer Institute (NCI) molecular database. Fan C, Huang YX, Bao YL, Sun LG, Wu Y, Yu CL, Zhang Y, Song ZB, Zheng LH, Sun Y, Wang GN, Li YX. Int J Mol Sci 13 17185-17209 (2012)
  144. A noncommutative combinatorial protein logic circuit controls cell orientation in nanoenvironments. Chen J, Vishweshwaraiah YL, Mailman RB, Tabdanov ED, Dokholyan NV. Sci Adv 9 eadg1062 (2023)
  145. ATP-site inhibitors induce unique conformations of the acute myeloid leukemia-associated Src-family kinase, Fgr. Du S, Alvarado JJ, Wales TE, Moroco JA, Engen JR, Smithgall TE. Structure 30 1508-1517.e3 (2022)
  146. An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase. Ohkura K, Kawaguchi Y, Tatematsu Y, Uto Y, Hori H. Anticancer Res 36 3645-3649 (2016)
  147. An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function. Cuesta-Hernández HN, Contreras J, Soriano-Maldonado P, Sánchez-Wandelmer J, Yeung W, Martín-Hurtado A, Muñoz IG, Kannan N, Llimargas M, Muñoz J, Plaza-Menacho I. Nat Commun 14 6548 (2023)
  148. Antioxidant and Anti-Inflammatory Effects of 6,3',4´- and 7,3´,4´-Trihydroxyflavone on 2D and 3D RAW264.7 Models. Wang X, Cao Y, Chen S, Yang X, Bian J, Huang D. Antioxidants (Basel) 12 204 (2023)
  149. Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Kan Y, Paung Y, Kim Y, Seeliger MA, Miller WT. Biochemistry 62 1124-1137 (2023)
  150. Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition. Burikhanov R, Ganguly S, Ellingson S, Sviripa VM, Araujo N, Li S, Venkatraman P, Rao M, Choughule A, Brainson CF, Zhan CG, Spielmann HP, Watt DS, Govindan R, Rangnekar VM. Am J Cancer Res 13 976-991 (2023)
  151. Expression, purification and preliminary crystallographic studies of the C-terminal SH3 domain of human Tks4. Huang Y, Qian H, Wang X, Cheng Z, Ren J, Zhao W, Xie Y. Acta Crystallogr F Struct Biol Commun 70 343-346 (2014)
  152. Geometry of protein shape and its evolutionary pattern for function prediction and characterization. Liang J. Annu Int Conf IEEE Eng Med Biol Soc 2009 2324-2327 (2009)
  153. KC-180-2 Exerts Anti-SCLC Effects via Dual Inhibition of Tubulin Polymerization and Src Signaling. Peng J, Zeng Y, Hu X, Huang S, Gao X, Tian D, Tian S, Qiu L, Liu J, Dong R, Zhan W, Qin C, Guang B, Yang T. ACS Omega 7 32164-32175 (2022)
  154. Research on the Mechanism of Asperosaponin VI for Treating Recurrent Spontaneous Abortion by Bioinformatics Analysis and Experimental Validation. Xia B, Zhang P, Lai Y, Cui S, Chen Z, Yu Q, Wu H, Zeng L, Xie B, Li J, Zhang H, Luo S, Gao J. Evid Based Complement Alternat Med 2022 8099853 (2022)
  155. SHP-1 tyrosine phosphatase binding to c-Src kinase phosphor-dependent conformations: A comparative structural framework. Gul M, Navid A, Fakhar M, Rashid S. PLoS One 18 e0278448 (2023)
  156. Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics. Yang AY, Liu HL, Yang YF. Front Pharmacol 13 1072547 (2022)
  157. TYROSINE KINASES: COMPLEX MOLECULAR SYSTEMS CHALLENGING COMPUTATIONAL METHODOLOGIES. Thomas T, Roux B. Eur Phys J B 94 203 (2021)
  158. The Pharmit Backend: A Computer Systems Approach to Enabling Interactive Online Drug Discovery. Koes DR. IBM J Res Dev 62 1-6 (2018)
  159. The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound. Xie J, Gore JC. Curr Cancer Drug Targets 20 364-371 (2020)
  160. VEGF and EGFR signaling pathways are involved in the baicalein attenuation of OVA-induced airway inflammation and airway remodeling in mice. Peng W, Xia Q, Zhang Y, Cao D, Zheng X. Respir Res 25 10 (2024)


Reviews citing this publication (94)

  1. Cell signaling by receptor tyrosine kinases. Schlessinger J. Cell 103 211-225 (2000)
  2. Signaling--2000 and beyond. Hunter T. Cell 100 113-127 (2000)
  3. The conformational plasticity of protein kinases. Huse M, Kuriyan J. Cell 109 275-282 (2002)
  4. Mechanisms of specificity in protein phosphorylation. Ubersax JA, Ferrell JE. Nat Rev Mol Cell Biol 8 530-541 (2007)
  5. Protein tyrosine kinase structure and function. Hubbard SR, Till JH. Annu Rev Biochem 69 373-398 (2000)
  6. Src kinases: a hub for NMDA receptor regulation. Salter MW, Kalia LV. Nat Rev Neurosci 5 317-328 (2004)
  7. Protein kinases: evolution of dynamic regulatory proteins. Taylor SS, Kornev AP. Trends Biochem Sci 36 65-77 (2011)
  8. Structure and regulation of Src family kinases. Boggon TJ, Eck MJ. Oncogene 23 7918-7927 (2004)
  9. Src in cancer: deregulation and consequences for cell behaviour. Frame MC. Biochim Biophys Acta 1602 114-130 (2002)
  10. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Palacios EH, Weiss A. Oncogene 23 7990-8000 (2004)
  11. The hunting of the Src. Martin GS. Nat Rev Mol Cell Biol 2 467-475 (2001)
  12. c-Src and cooperating partners in human cancer. Ishizawar R, Parsons SJ. Cancer Cell 6 209-214 (2004)
  13. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L. Int J Mol Med 40 271-280 (2017)
  14. The interplay between Src and integrins in normal and tumor biology. Playford MP, Schaller MD. Oncogene 23 7928-7946 (2004)
  15. Src protein-tyrosine kinase structure and regulation. Roskoski R. Biochem Biophys Res Commun 324 1155-1164 (2004)
  16. ErbB receptors: from oncogenes to targeted cancer therapies. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. J Clin Invest 117 2051-2058 (2007)
  17. Selected glimpses into the activation and function of Src kinase. Bjorge JD, Jakymiw A, Fujita DJ. Oncogene 19 5620-5635 (2000)
  18. Regulation of signal transduction pathways by estrogen and progesterone. Edwards DP. Annu Rev Physiol 67 335-376 (2005)
  19. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Bretscher A, Chambers D, Nguyen R, Reczek D. Annu Rev Cell Dev Biol 16 113-143 (2000)
  20. Src family tyrosine kinases and growth factor signaling. Abram CL, Courtneidge SA. Exp Cell Res 254 1-13 (2000)
  21. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. Immunol Rev 228 9-22 (2009)
  22. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Roskoski R. Pharmacol Res 94 9-25 (2015)
  23. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Mol Cell 42 9-22 (2011)
  24. Phosphotyrosine-binding domains in signal transduction. Yaffe MB. Nat Rev Mol Cell Biol 3 177-186 (2002)
  25. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. Kumar A, Petri ET, Halmos B, Boggon TJ. J Clin Oncol 26 1742-1751 (2008)
  26. Magic bullets for protein kinases. Bishop AC, Buzko O, Shokat KM. Trends Cell Biol 11 167-172 (2001)
  27. Autoinhibitory domains: modular effectors of cellular regulation. Pufall MA, Graves BJ. Annu Rev Cell Dev Biol 18 421-462 (2002)
  28. The structure, regulation, and function of ZAP-70. Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, Weiss A. Immunol Rev 228 41-57 (2009)
  29. T-cell signaling regulated by the Tec family kinase, Itk. Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ. Cold Spring Harb Perspect Biol 2 a002287 (2010)
  30. Variation on an Src-like theme. Harrison SC. Cell 112 737-740 (2003)
  31. Progesterone receptor transcription and non-transcription signaling mechanisms. Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Steroids 68 761-770 (2003)
  32. Rapid actions of steroid receptors in cellular signaling pathways. Cato AC, Nestl A, Mink S. Sci STKE 2002 re9 (2002)
  33. Role of linkers in communication between protein modules. Gokhale RS, Khosla C. Curr Opin Chem Biol 4 22-27 (2000)
  34. Lipid rafts in T cell receptor signalling . Kabouridis PS. Mol Membr Biol 23 49-57 (2006)
  35. Src-family kinases in B-cell development and signaling. Gauld SB, Cambier JC. Oncogene 23 8001-8006 (2004)
  36. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. Chiarugi P, Buricchi F. Antioxid Redox Signal 9 1-24 (2007)
  37. The road to Src. Martin GS. Oncogene 23 7910-7917 (2004)
  38. The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Duan L, Reddi AL, Ghosh A, Dimri M, Band H. Immunity 21 7-17 (2004)
  39. The capable ABL: what is its biological function? Wang JY. Mol Cell Biol 34 1188-1197 (2014)
  40. Lipid rafts in T cell signalling and disease. Jury EC, Flores-Borja F, Kabouridis PS. Semin Cell Dev Biol 18 608-615 (2007)
  41. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Alexander DR. Semin Immunol 12 349-359 (2000)
  42. Structural modes of stabilization of permissive phosphorylation sites in protein kinases: distinct strategies in Ser/Thr and Tyr kinases. Krupa A, Preethi G, Srinivasan N. J Mol Biol 339 1025-1039 (2004)
  43. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Masson K, Rönnstrand L. Cell Signal 21 1717-1726 (2009)
  44. Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases. Marx A, Nugoor C, Panneerselvam S, Mandelkow E. FASEB J 24 1637-1648 (2010)
  45. SH2 domains: modulators of nonreceptor tyrosine kinase activity. Filippakopoulos P, Müller S, Knapp S. Curr Opin Struct Biol 19 643-649 (2009)
  46. Protein-protein interactions in the allosteric regulation of protein kinases. Pellicena P, Kuriyan J. Curr Opin Struct Biol 16 702-709 (2006)
  47. Regulation of T-cell receptor signalling by membrane microdomains. Razzaq TM, Ozegbe P, Jury EC, Sembi P, Blackwell NM, Kabouridis PS. Immunology 113 413-426 (2004)
  48. Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling. Wagner MJ, Stacey MM, Liu BA, Pawson T. Cold Spring Harb Perspect Biol 5 a008987 (2013)
  49. Retroviral oncogenes: a historical primer. Vogt PK. Nat Rev Cancer 12 639-648 (2012)
  50. Kinome signaling through regulated protein-protein interactions in normal and cancer cells. Pawson T, Kofler M. Curr Opin Cell Biol 21 147-153 (2009)
  51. On the molecular mechanisms of mitotic kinase activation. Bayliss R, Fry A, Haq T, Yeoh S. Open Biol 2 120136 (2012)
  52. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Kim MP, Park SI, Kopetz S, Gallick GE. Cell Tissue Res 335 249-259 (2009)
  53. Structural aspects of protein kinase control-role of conformational flexibility. Engh RA, Bossemeyer D. Pharmacol Ther 93 99-111 (2002)
  54. Designing bisubstrate analog inhibitors for protein kinases. Parang K, Cole PA. Pharmacol Ther 93 145-157 (2002)
  55. Structure/function studies of Ser/Thr and Tyr protein phosphorylation in Mycobacterium tuberculosis. Greenstein AE, Grundner C, Echols N, Gay LM, Lombana TN, Miecskowski CA, Pullen KE, Sung PY, Alber T. J Mol Microbiol Biotechnol 9 167-181 (2005)
  56. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Egloff AM, Grandis JR. Semin Oncol 35 286-297 (2008)
  57. Protein kinases in vascular smooth muscle tone--role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Ward JP, Knock GA, Snetkov VA, Aaronson PI. Pharmacol Ther 104 207-231 (2004)
  58. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. Furukawa T, Kurokawa J. Pharmacol Ther 115 106-115 (2007)
  59. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Susva M, Missbach M, Green J. Trends Pharmacol Sci 21 489-495 (2000)
  60. Redox regulation of the actin cytoskeleton and its role in the vascular system. Xu Q, Huff LP, Fujii M, Griendling KK. Free Radic Biol Med 109 84-107 (2017)
  61. Mechanisms for redox-regulation of protein kinase C. Steinberg SF. Front Pharmacol 6 128 (2015)
  62. Protein Regulation in Signal Transduction. Lee MJ, Yaffe MB. Cold Spring Harb Perspect Biol 8 a005918 (2016)
  63. Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways. Dunican DJ, Doherty P. Biopolymers 60 45-60 (2001)
  64. Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease. MacKay CE, Knock GA. J Physiol 593 3815-3828 (2015)
  65. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Bose R, Zhang X. Exp Cell Res 315 649-658 (2009)
  66. Estrogen receptors in gastric cancer: Advances and perspectives. Ur Rahman MS, Cao J. World J Gastroenterol 22 2475-2482 (2016)
  67. Endocytosis and the Src family of non-receptor tyrosine kinases. Reinecke J, Caplan S. Biomol Concepts 5 143-155 (2014)
  68. Proteus in the world of proteins: conformational changes in protein kinases. Rabiller M, Getlik M, Klüter S, Richters A, Tückmantel S, Simard JR, Rauh D. Arch Pharm (Weinheim) 343 193-206 (2010)
  69. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Dengjel J, Kratchmarova I, Blagoev B. Mol Biosyst 5 1112-1121 (2009)
  70. Tyrosine kinase signaling and the emergence of multicellularity. Miller WT. Biochim Biophys Acta 1823 1053-1057 (2012)
  71. Whither structural biology? Harrison SC. Nat Struct Mol Biol 11 12-15 (2004)
  72. Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. de Oliveira GA, Rangel LP, Costa DC, Silva JL. Front Oncol 5 97 (2015)
  73. The protein kinase activity modulation sites: mechanisms for cellular regulation - targets for therapeutic intervention. Engh RA, Bossemeyer D. Adv Enzyme Regul 41 121-149 (2001)
  74. Lyn, Lupus, and (B) Lymphocytes, a Lesson on the Critical Balance of Kinase Signaling in Immunity. Brodie EJ, Infantino S, Low MSY, Tarlinton DM. Front Immunol 9 401 (2018)
  75. Src inhibitors: genomics to therapeutics. Sawyer T, Boyce B, Dalgarno D, Iuliucci J. Expert Opin Investig Drugs 10 1327-1344 (2001)
  76. Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. Fischer PM. Med Res Rev 37 314-367 (2017)
  77. Evolution of a dynamic molecular switch. Taylor SS, Meharena HS, Kornev AP. IUBMB Life 71 672-684 (2019)
  78. Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Johnson DE. Adv Enzyme Regul 48 98-112 (2008)
  79. Pathways of metastasis suppression in bladder cancer. Said N, Theodorescu D. Cancer Metastasis Rev 28 327-333 (2009)
  80. Sin: good or bad? A T lymphocyte perspective. Alexandropoulos K, Donlin LT, Xing L, Regelmann AG. Immunol Rev 192 181-195 (2003)
  81. The principle of conformational signaling. Tompa P. Chem Soc Rev 45 4252-4284 (2016)
  82. Use of stable isotope labeling by amino acids in cell culture (SILAC) for phosphotyrosine protein identification and quantitation. Zhang G, Neubert TA. Methods Mol Biol 527 79-92, xi (2009)
  83. Src family kinases and their role in hematological malignancies. Ku M, Wall M, MacKinnon RN, Walkley CR, Purton LE, Tam C, Izon D, Campbell L, Cheng HC, Nandurkar H. Leuk Lymphoma 56 577-586 (2015)
  84. Nuclear Functions of the Tyrosine Kinase Src. Bagnato G, Leopizzi M, Urciuoli E, Peruzzi B. Int J Mol Sci 21 E2675 (2020)
  85. The T-cell-specific adapter protein family: TSAd, ALX, and SH2D4A/SH2D4B. Lapinski PE, Oliver JA, Bodie JN, Marti F, King PD. Immunol Rev 232 240-254 (2009)
  86. Bruton's TK inhibitors: structural insights and evolution of clinical candidates. Xing L, Huang A. Future Med Chem 6 675-695 (2014)
  87. Advances in the design of ITK inhibitors. Charrier JD, Knegtel RM. Expert Opin Drug Discov 8 369-381 (2013)
  88. Src Family Protein Kinase Controls the Fate of B Cells in Autoimmune Diseases. Zhang X, Mei D, Zhang L, Wei W. Inflammation 44 423-433 (2021)
  89. Protein kinases: From targets to anti-cancer drugs. Cruzalegui F. Ann Pharm Fr 68 254-259 (2010)
  90. A Novel Biallelic LCK Variant Resulting in Profound T-Cell Immune Deficiency and Review of the Literature. Lanz AL, Erdem S, Ozcan A, Ceylaner G, Cansever M, Ceylaner S, Conca R, Magg T, Acuto O, Latour S, Klein C, Patiroglu T, Unal E, Eken A, Hauck F. J Clin Immunol 44 1 (2023)
  91. ACKnowledging the role of the Activated-Cdc42 associated kinase (ACK) in regulating protein stability in cancer. Hodder S, Fox M, Binti Ahmad Mokhtar AM, Mott HR, Owen D. Small GTPases 14 14-25 (2023)
  92. Atomic evidence: the foundations of structural molecular biology. Goodsell DS. Sci Prog 94 414-430 (2011)
  93. Ca2+ Signaling and Src Functions in Tumor Cells. Villalobo A. Biomolecules 13 1739 (2023)
  94. Dissection of the catalytic and regulatory structure-function relationships of Csk protein tyrosine kinase. Sun G, Ayrapetov MK. Front Cell Dev Biol 11 1148352 (2023)

Articles citing this publication (348)

  1. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. Cell 125 1137-1149 (2006)
  2. Intrinsic disorder in cell-signaling and cancer-associated proteins. Iakoucheva LM, Brown CJ, Lawson JD, Obradović Z, Dunker AK. J Mol Biol 323 573-584 (2002)
  3. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Cell 112 859-871 (2003)
  4. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. EMBO J 19 5406-5417 (2000)
  5. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Azam M, Latek RR, Daley GQ. Cell 112 831-843 (2003)
  6. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC. Cell 102 387-397 (2000)
  7. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP. Mol Cell 8 269-280 (2001)
  8. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Okamura H, Aramburu J, García-Rodríguez C, Viola JP, Raghavan A, Tahiliani M, Zhang X, Qin J, Hogan PG, Rao A. Mol Cell 6 539-550 (2000)
  9. The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Durocher D, Taylor IA, Sarbassova D, Haire LF, Westcott SL, Jackson SP, Smerdon SJ, Yaffe MB. Mol Cell 6 1169-1182 (2000)
  10. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ. J Cell Biol 157 265-275 (2002)
  11. Src tyrosine kinase is a novel direct effector of G proteins. Ma YC, Huang J, Ali S, Lowry W, Huang XY. Cell 102 635-646 (2000)
  12. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. Cell 105 115-126 (2001)
  13. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Mol Cell 3 639-648 (1999)
  14. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, Levy J, Gailit J, Bowtell D, Horne WC, Baron R. J Cell Biol 152 181-195 (2001)
  15. Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, Fugger L, Polzella P, Cerundolo V, Dushek O, Höfer T, Viola A, Acuto O. Immunity 32 766-777 (2010)
  16. How viruses hijack cell regulation. Davey NE, Davey NE, Travé G, Gibson TJ. Trends Biochem Sci 36 159-169 (2011)
  17. Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development. Arnaud L, Ballif BA, Förster E, Cooper JA. Curr Biol 13 9-17 (2003)
  18. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Proc Natl Acad Sci U S A 106 21608-21613 (2009)
  19. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. Structure 13 861-871 (2005)
  20. A Src-like inactive conformation in the abl tyrosine kinase domain. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, Karplus M, Cole PA, Kuriyan J. PLoS Biol 4 e144 (2006)
  21. Allosteric activation of functionally asymmetric RAF kinase dimers. Hu J, Stites EC, Yu H, Yu H, Germino EA, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS. Cell 154 1036-1046 (2013)
  22. Heme is involved in microRNA processing. Faller M, Matsunaga M, Yin S, Loo JA, Guo F. Nat Struct Mol Biol 14 23-29 (2007)
  23. Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Deindl S, Kadlecek TA, Brdicka T, Cao X, Weiss A, Kuriyan J. Cell 129 735-746 (2007)
  24. The Helicobacter pylori CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. Selbach M, Moese S, Hurwitz R, Hauck CR, Meyer TF, Backert S. EMBO J 22 515-528 (2003)
  25. Structural evolution of the protein kinase-like superfamily. Scheeff ED, Bourne PE. PLoS Comput Biol 1 e49 (2005)
  26. Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Young TA, Delagoutte B, Endrizzi JA, Falick AM, Alber T. Nat Struct Biol 10 168-174 (2003)
  27. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Holdorf AD, Lee KH, Burack WR, Allen PM, Shaw AS. Nat Immunol 3 259-264 (2002)
  28. Conformational states of the kinase Lck regulate clustering in early T cell signaling. Rossy J, Owen DM, Williamson DJ, Yang Z, Gaus K. Nat Immunol 14 82-89 (2013)
  29. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. Jia R, Pan Q, Ding S, Rong L, Liu SL, Geng Y, Qiao W, Liang C. J Virol 86 13697-13707 (2012)
  30. VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Garrett TA, Van Buul JD, Burridge K. Exp Cell Res 313 3285-3297 (2007)
  31. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Saharinen P, Vihinen M, Silvennoinen O. Mol Biol Cell 14 1448-1459 (2003)
  32. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. Structure 15 299-311 (2007)
  33. Ubiquitin-mediated degradation of active Src tyrosine kinase. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, Howley PM. Proc Natl Acad Sci U S A 96 13738-13743 (1999)
  34. Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? Kannan N, Neuwald AF. J Mol Biol 351 956-972 (2005)
  35. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, Yu C, Shaw AS, Manning G, Skelton NJ, Hymowitz SG, Malek S. Cancer Cell 29 477-493 (2016)
  36. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G. Biochem J 430 425-437 (2010)
  37. The geometry of domain combination in proteins. Bashton M, Chothia C. J Mol Biol 315 927-939 (2002)
  38. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM. Cancer Biol Ther 8 696-703 (2009)
  39. Myristoylation and membrane binding regulate c-Src stability and kinase activity. Patwardhan P, Resh MD. Mol Cell Biol 30 4094-4107 (2010)
  40. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. Mol Cell Biol 23 3884-3896 (2003)
  41. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. Am J Pathol 170 366-376 (2007)
  42. Cisplatin-induced activation of the EGF receptor. Benhar M, Engelberg D, Levitzki A. Oncogene 21 8723-8731 (2002)
  43. ATPase-dependent role of the atypical kinase Rio2 on the evolving pre-40S ribosomal subunit. Ferreira-Cerca S, Sagar V, Schäfer T, Diop M, Wesseling AM, Lu H, Chai E, Hurt E, LaRonde-LeBlanc N. Nat Struct Mol Biol 19 1316-1323 (2012)
  44. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. Alghisi GC, Ponsonnet L, Rüegg C. PLoS One 4 e4449 (2009)
  45. In vitro membrane reconstitution of the T-cell receptor proximal signaling network. Hui E, Vale RD. Nat Struct Mol Biol 21 133-142 (2014)
  46. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Oncogene 30 561-574 (2011)
  47. Conversion of mechanical force into biochemical signaling. Han B, Bai XH, Lodyga M, Xu J, Yang BB, Keshavjee S, Post M, Liu M. J Biol Chem 279 54793-54801 (2004)
  48. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Sutto L, Gervasio FL. Proc Natl Acad Sci U S A 110 10616-10621 (2013)
  49. Defining a new nomenclature for the structures of active and inactive kinases. Modi V, Dunbrack RL. Proc Natl Acad Sci U S A 116 6818-6827 (2019)
  50. Crystal structure of an inactive Akt2 kinase domain. Huang X, Begley M, Morgenstern KA, Gu Y, Rose P, Zhao H, Zhu X. Structure 11 21-30 (2003)
  51. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT, Fan ST. Carcinogenesis 29 2096-2105 (2008)
  52. Pairs of dipeptides synergistically activate the binding of substrate by ubiquitin ligase through dissociation of its autoinhibitory domain. Du F, Navarro-Garcia F, Xia Z, Tasaki T, Varshavsky A. Proc Natl Acad Sci U S A 99 14110-14115 (2002)
  53. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Senis YA, Tomlinson MG, Ellison S, Mazharian A, Lim J, Zhao Y, Kornerup KN, Auger JM, Thomas SG, Dhanjal T, Kalia N, Zhu JW, Weiss A, Watson SP. Blood 113 4942-4954 (2009)
  54. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Ishizawar RC, Miyake T, Parsons SJ. Oncogene 26 3503-3510 (2007)
  55. Functions of the Lyn tyrosine kinase in health and disease. Ingley E. Cell Commun Signal 10 21 (2012)
  56. Biochemical characterization of the Arabidopsis protein kinase SOS2 that functions in salt tolerance. Gong D, Guo Y, Jagendorf AT, Zhu JK. Plant Physiol 130 256-264 (2002)
  57. Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Eswaran J, Lee WH, Debreczeni JE, Filippakopoulos P, Turnbull A, Fedorov O, Deacon SW, Peterson JR, Knapp S. Structure 15 201-213 (2007)
  58. Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells. Liu Y, Senger DR. FASEB J 18 457-468 (2004)
  59. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Qi J, Wang J, Romanyuk O, Siu CH. Mol Biol Cell 17 1261-1272 (2006)
  60. Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Yang S, Banavali NK, Roux B. Proc Natl Acad Sci U S A 106 3776-3781 (2009)
  61. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Wei L, Yang Y, Zhang X, Yu Q. Oncogene 23 9052-9061 (2004)
  62. The active conformation of the PAK1 kinase domain. Lei M, Robinson MA, Harrison SC. Structure 13 769-778 (2005)
  63. Transmodulation between phospholipase D and c-Src enhances cell proliferation. Ahn BH, Kim SY, Kim EH, Choi KS, Kwon TK, Lee YH, Chang JS, Kim MS, Jo YH, Min DS. Mol Cell Biol 23 3103-3115 (2003)
  64. Ligand-induced global transitions in the catalytic domain of protein kinase A. Hyeon C, Jennings PA, Adams JA, Onuchic JN. Proc Natl Acad Sci U S A 106 3023-3028 (2009)
  65. A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. Lin CH, Hare BJ, Wagner G, Harrison SC, Maniatis T, Fraenkel E. Mol Cell 8 581-590 (2001)
  66. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Sci Signal 7 ra114 (2014)
  67. Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Herraiz C, Journé F, Abdel-Malek Z, Ghanem G, Jiménez-Cervantes C, García-Borrón JC. Mol Endocrinol 25 138-156 (2011)
  68. Src kinase conformational activation: thermodynamics, pathways, and mechanisms. Yang S, Roux B. PLoS Comput Biol 4 e1000047 (2008)
  69. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL, Levy RM. J Med Chem 58 466-479 (2015)
  70. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Agafonov RV, Wilson C, Otten R, Buosi V, Kern D. Nat Struct Mol Biol 21 848-853 (2014)
  71. Interactions between Src family protein tyrosine kinases and PSD-95. Kalia LV, Salter MW. Neuropharmacology 45 720-728 (2003)
  72. Molecular determinants for ATP-binding in proteins: a data mining and quantum chemical analysis. Mao L, Wang Y, Liu Y, Hu X. J Mol Biol 336 787-807 (2004)
  73. XB130, a novel adaptor protein for signal transduction. Xu J, Bai XH, Lodyga M, Han B, Xiao H, Keshavjee S, Hu J, Zhang H, Yang BB, Liu M. J Biol Chem 282 16401-16412 (2007)
  74. Repetitive deformation activates focal adhesion kinase and ERK mitogenic signals in human Caco-2 intestinal epithelial cells through Src and Rac1. Chaturvedi LS, Marsh HM, Shang X, Zheng Y, Basson MD. J Biol Chem 282 14-28 (2007)
  75. Src and focal adhesion kinase mediate mechanical strain-induced proliferation and ERK1/2 phosphorylation in human H441 pulmonary epithelial cells. Chaturvedi LS, Marsh HM, Basson MD. Am J Physiol Cell Physiol 292 C1701-13 (2007)
  76. Both src-dependent and -independent mechanisms mediate phosphatidylinositol 3-kinase regulation of colony-stimulating factor 1-activated mitogen-activated protein kinases in myeloid progenitors. Lee AW, States DJ. Mol Cell Biol 20 6779-6798 (2000)
  77. Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion. Li L, Okura M, Imamoto A. Mol Cell Biol 22 1203-1217 (2002)
  78. Structural basis for peptide binding in protein kinase A. Role of glutamic acid 203 and tyrosine 204 in the peptide-positioning loop. Moore MJ, Adams JA, Taylor SS. J Biol Chem 278 10613-10618 (2003)
  79. Trafficking of Lyn through the Golgi caveolin involves the charged residues on alphaE and alphaI helices in the kinase domain. Kasahara K, Nakayama Y, Ikeda K, Fukushima Y, Matsuda D, Horimoto S, Yamaguchi N. J Cell Biol 165 641-652 (2004)
  80. The role of backbone motions in ligand binding to the c-Src SH3 domain. Wang C, Pawley NH, Nicholson LK. J Mol Biol 313 873-887 (2001)
  81. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ. Proc Natl Acad Sci U S A 112 E5381-90 (2015)
  82. T cell activation results in conformational changes in the Src family kinase Lck to induce its activation. Stirnweiss A, Hartig R, Gieseler S, Lindquist JA, Reichardt P, Philipsen L, Simeoni L, Poltorak M, Merten C, Zuschratter W, Prokazov Y, Paster W, Stockinger H, Harder T, Gunzer M, Schraven B. Sci Signal 6 ra13 (2013)
  83. Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Li L, Hisamoto K, Kim KH, Haynes MP, Bauer PM, Sanjay A, Collinge M, Baron R, Sessa WC, Bender JR. Proc Natl Acad Sci U S A 104 16468-16473 (2007)
  84. A systematic comparative and structural analysis of protein phosphorylation sites based on the mtcPTM database. Jiménez JL, Hegemann B, Hutchins JR, Peters JM, Durbin R. Genome Biol 8 R90 (2007)
  85. Conformational disturbance in Abl kinase upon mutation and deregulation. Iacob RE, Pene-Dumitrescu T, Zhang J, Gray NS, Smithgall TE, Engen JR. Proc Natl Acad Sci U S A 106 1386-1391 (2009)
  86. Integrin-induced tyrosine phosphorylation of protein-tyrosine phosphatase-alpha is required for cytoskeletal reorganization and cell migration. Chen M, Chen SC, Pallen CJ. J Biol Chem 281 11972-11980 (2006)
  87. Src phosphorylation of Alix/AIP1 modulates its interaction with binding partners and antagonizes its activities. Schmidt MHH, Dikic I, Bögler O. J Biol Chem 280 3414-3425 (2005)
  88. Endosomal-sorting complexes required for transport (ESCRT) pathway-dependent endosomal traffic regulates the localization of active Src at focal adhesions. Tu C, Ortega-Cava CF, Winograd P, Stanton MJ, Reddi AL, Dodge I, Arya R, Dimri M, Clubb RJ, Naramura M, Wagner KU, Band V, Band H. Proc Natl Acad Sci U S A 107 16107-16112 (2010)
  89. The sea urchin kinome: a first look. Bradham CA, Foltz KR, Beane WS, Arnone MI, Rizzo F, Coffman JA, Mushegian A, Goel M, Morales J, Geneviere AM, Lapraz F, Robertson AJ, Kelkar H, Loza-Coll M, Townley IK, Raisch M, Roux MM, Lepage T, Gache C, McClay DR, Manning G. Dev Biol 300 180-193 (2006)
  90. Structural characterization of the natively unfolded N-terminal domain of human c-Src kinase: insights into the role of phosphorylation of the unique domain. Pérez Y, Gairí M, Pons M, Bernadó P. J Mol Biol 391 136-148 (2009)
  91. Activation of NMDA receptors and L-type voltage-gated calcium channels mediates enhanced formation of Fyn-PSD95-NR2A complex after transient brain ischemia. Hou XY, Zhang GY, Yan JZ, Chen M, Liu Y. Brain Res 955 123-132 (2002)
  92. Phosphorylation-dependent and phosphorylation-independent modes of modulation of shaker family voltage-gated potassium channels by SRC family protein tyrosine kinases. Nitabach MN, Llamas DA, Thompson IJ, Collins KA, Holmes TC. J Neurosci 22 7913-7922 (2002)
  93. The spatiotemporal pattern of Src activation at lipid rafts revealed by diffusion-corrected FRET imaging. Lu S, Ouyang M, Seong J, Zhang J, Chien S, Wang Y. PLoS Comput Biol 4 e1000127 (2008)
  94. An improved method for distinguishing between anisotropic tumbling and chemical exchange in analysis of 15N relaxation parameters. Pawley NH, Wang C, Koide S, Nicholson LK. J Biomol NMR 20 149-165 (2001)
  95. Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. Kuglstatter A, Villaseñor AG, Shaw D, Lee SW, Tsing S, Niu L, Song KW, Barnett JW, Browner MF. J Immunol 178 2641-2645 (2007)
  96. Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. Prince T, Matts RL. J Biol Chem 279 39975-39981 (2004)
  97. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. Pene-Dumitrescu T, Smithgall TE. J Biol Chem 285 21446-21457 (2010)
  98. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. Aleksandrov A, Simonson T. J Biol Chem 285 13807-13815 (2010)
  99. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, Druker BJ, McCarty OJ. Thromb Res 135 155-160 (2015)
  100. H-Ras modulates N-methyl-D-aspartate receptor function via inhibition of Src tyrosine kinase activity. Thornton C, Yaka R, Dinh S, Ron D. J Biol Chem 278 23823-23829 (2003)
  101. Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation. Luciano F, Ricci JE, Auberger P. Oncogene 20 4935-4941 (2001)
  102. Crystal structures of active SRC kinase domain complexes. Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, Koch S, Schäfer W, Huber R, Engh RA. J Mol Biol 353 222-231 (2005)
  103. Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCζ-dependent manner in vascular smooth muscle cells. Xi G, Shen X, Maile LA, Wai C, Gollahon K, Clemmons DR. Diabetes 61 104-113 (2012)
  104. A conserved dimer and global conformational changes in the structure of apo-PknE Ser/Thr protein kinase from Mycobacterium tuberculosis. Gay LM, Ng HL, Alber T. J Mol Biol 360 409-420 (2006)
  105. Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. Edwards DP, Wardell SE, Boonyaratanakornkit V. J Steroid Biochem Mol Biol 83 173-186 (2002)
  106. Developmentally regulated dual-specificity kinase from peanut that is induced by abiotic stresses. Rudrabhatla P, Rajasekharan R. Plant Physiol 130 380-390 (2002)
  107. Galpha and Gbeta gamma require distinct Src-dependent pathways to activate Rap1 and Ras. Schmitt JM, Stork PJ. J Biol Chem 277 43024-43032 (2002)
  108. Mutant tyrosine kinases with unnatural nucleotide specificity retain the structure and phospho-acceptor specificity of the wild-type enzyme. Witucki LA, Huang X, Shah K, Liu Y, Kyin S, Eck MJ, Shokat KM. Chem Biol 9 25-33 (2002)
  109. The N-terminal end of the catalytic domain of SRC kinase Hck is a conformational switch implicated in long-range allosteric regulation. Banavali NK, Roux B. Structure 13 1715-1723 (2005)
  110. Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2. Marx A, Nugoor C, Müller J, Panneerselvam S, Timm T, Bilang M, Mylonas E, Svergun DI, Mandelkow EM, Mandelkow E. J Biol Chem 281 27586-27599 (2006)
  111. How does the kinase Lck phosphorylate the T cell receptor? Spatial organization as a regulatory mechanism. Rossy J, Williamson DJ, Gaus K. Front Immunol 3 167 (2012)
  112. Activation of the Src family kinase Hck without SH3-linker release. Lerner EC, Trible RP, Schiavone AP, Hochrein JM, Engen JR, Smithgall TE. J Biol Chem 280 40832-40837 (2005)
  113. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Jacobs MD, Caron PR, Hare BJ. Proteins 70 1451-1460 (2008)
  114. Adaptor protein Shc is an isoform-specific direct activator of the tyrosine kinase c-Src. Sato K, Nagao T, Kakumoto M, Kimoto M, Otsuki T, Iwasaki T, Tokmakov AA, Owada K, Fukami Y. J Biol Chem 277 29568-29576 (2002)
  115. Molecular interaction maps as information organizers and simulation guides. Kohn KW. Chaos 11 84-97 (2001)
  116. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B. Proteins 44 32-43 (2001)
  117. Structural characterization of the active and inactive states of Src kinase in solution by small-angle X-ray scattering. Bernadó P, Pérez Y, Svergun DI, Pons M. J Mol Biol 376 492-505 (2008)
  118. The NADPH Oxidases DUOX1 and NOX2 Play Distinct Roles in Redox Regulation of Epidermal Growth Factor Receptor Signaling. Heppner DE, Hristova M, Dustin CM, Danyal K, Habibovic A, van der Vliet A. J Biol Chem 291 23282-23293 (2016)
  119. An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen/deuterium exchange and mass spectrometry. Hochrein JM, Lerner EC, Schiavone AP, Smithgall TE, Engen JR. Protein Sci 15 65-73 (2006)
  120. Competing protein:protein interactions are proposed to control the biological switch of the E coli biotin repressor. Weaver LH, Kwon K, Beckett D, Matthews BW. Protein Sci 10 2618-2622 (2001)
  121. Phosphorylation site dynamics of early T-cell receptor signaling. Chylek LA, Akimov V, Dengjel J, Rigbolt KT, Hu B, Hlavacek WS, Blagoev B. PLoS One 9 e104240 (2014)
  122. The Unique Domain Forms a Fuzzy Intramolecular Complex in Src Family Kinases. Arbesú M, Maffei M, Cordeiro TN, Teixeira JM, Pérez Y, Bernadó P, Roche S, Pons M. Structure 25 630-640.e4 (2017)
  123. Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck. Banavali NK, Roux B. Proteins 67 1096-1112 (2007)
  124. Differential regulation of endothelial cell permeability by high and low doses of oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine. Starosta V, Wu T, Zimman A, Pham D, Tian X, Oskolkova O, Bochkov V, Berliner JA, Birukova AA, Birukov KG. Am J Respir Cell Mol Biol 46 331-341 (2012)
  125. Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes. Matsumoto T, Kobayashi T, Ishida K, Taguchi K, Kamata K. Br J Pharmacol 160 1092-1104 (2010)
  126. Function of a sea urchin egg Src family kinase in initiating Ca2+ release at fertilization. Giusti AF, O'Neill FJ, Yamasu K, Foltz KR, Jaffe LA. Dev Biol 256 367-378 (2003)
  127. Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization. Haq T, Richards MW, Burgess SG, Gallego P, Yeoh S, O'Regan L, Reverter D, Roig J, Fry AM, Bayliss R. Nat Commun 6 8771 (2015)
  128. Oncogenic mutations reduce the stability of SRC kinase. Falsone SF, Leptihn S, Osterauer A, Haslbeck M, Buchner J. J Mol Biol 344 281-291 (2004)
  129. Selective interaction of LAT (linker of activated T cells) with the open-active form of Lck in lipid rafts reveals a new mechanism for the regulation of Lck in T cells. Kabouridis PS. Biochem J 371 907-915 (2003)
  130. The v-Src SH3 domain facilitates a cell adhesion-independent association with focal adhesion kinase. Hauck CR, Hunter T, Schlaepfer DD. J Biol Chem 276 17653-17662 (2001)
  131. Interaction between src family kinases and rho-kinase in agonist-induced Ca2+-sensitization of rat pulmonary artery. Knock GA, Shaifta Y, Snetkov VA, Vowles B, Drndarski S, Ward JP, Aaronson PI. Cardiovasc Res 77 570-579 (2008)
  132. Phosphorylated alpha-actinin and protein-tyrosine phosphatase 1B coregulate the disassembly of the focal adhesion kinase x Src complex and promote cell migration. Zhang Z, Zhang Z, Lin SY, Neel BG, Haimovich B. J Biol Chem 281 1746-1754 (2006)
  133. Src kinase is a direct target of apigenin against UVB-induced skin inflammation. Byun S, Park J, Lee E, Lim S, Yu JG, Lee SJ, Chen H, Dong Z, Lee KW, Lee HJ. Carcinogenesis 34 397-405 (2013)
  134. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T. Chem Biol Drug Des 67 46-57 (2006)
  135. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE. Oncogene 27 7055-7069 (2008)
  136. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. Prieto-Echagüe V, Gucwa A, Craddock BP, Brown DA, Miller WT. J Biol Chem 285 10605-10615 (2010)
  137. De novo phosphorylation and conformational opening of the tyrosine kinase Lck act in concert to initiate T cell receptor signaling. Philipsen L, Reddycherla AV, Hartig R, Gumz J, Kästle M, Kritikos A, Poltorak MP, Prokazov Y, Turbin E, Weber A, Zuschratter W, Schraven B, Simeoni L, Müller AJ. Sci Signal 10 eaaf4736 (2017)
  138. Fyn is required for haloperidol-induced catalepsy in mice. Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S. J Biol Chem 281 7129-7135 (2006)
  139. Isoproterenol induces actin depolymerization in human airway smooth muscle cells via activation of an Src kinase and GS. Hirshman CA, Zhu D, Pertel T, Panettieri RA, Emala CW. Am J Physiol Lung Cell Mol Physiol 288 L924-31 (2005)
  140. Role of src-family kinases in hypoxic vasoconstriction of rat pulmonary artery. Knock GA, Snetkov VA, Shaifta Y, Drndarski S, Ward JP, Aaronson PI. Cardiovasc Res 80 453-462 (2008)
  141. The human kinome and kinase inhibition. Duong-Ly KC, Peterson JR. Curr Protoc Pharmacol Chapter 2 Unit2.9 (2013)
  142. Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis. Yan N, Zhang S, Yang Y, Cheng L, Li C, Dai L, Dai L, Zhang X, Fan P, Tian H, Wang R, Chen X, Su X, Li Y, Zhang J, Du T, Wei Y, Deng H. Cancer Sci 103 1631-1639 (2012)
  143. Transition between proliferation and differentiation for lens epithelial cells is regulated by Src family kinases. Walker JL, Zhang L, Menko AS. Dev Dyn 224 361-372 (2002)
  144. A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase. Bamberger M, Santos AM, Gonçalves CM, Oliveira MI, James JR, Moreira A, Lozano F, Davis SJ, Carmo AM. J Biol Chem 286 30324-30336 (2011)
  145. Changes in the free-energy landscape of p38α MAP kinase through its canonical activation and binding events as studied by enhanced molecular dynamics simulations. Kuzmanic A, Sutto L, Saladino G, Nebreda AR, Gervasio FL, Orozco M. Elife 6 e22175 (2017)
  146. Ligand-induced strain in hydrogen bonds of the c-Src SH3 domain detected by NMR. Cordier F, Wang C, Grzesiek S, Nicholson LK. J Mol Biol 304 497-505 (2000)
  147. Structure of the pseudokinase domain of BIR2, a regulator of BAK1-mediated immune signaling in Arabidopsis. Blaum BS, Mazzotta S, Nöldeke ER, Halter T, Madlung J, Kemmerling B, Stehle T. J Struct Biol 186 112-121 (2014)
  148. Regulation of sodium pump endocytosis by cardiotonic steroids: Molecular mechanisms and physiological implications. Liu J, Shapiro JI. Pathophysiology 14 171-181 (2007)
  149. αC helix as a switch in the conformational transition of Src/CDK-like kinase domains. Huang H, Zhao R, Dickson BM, Skeel RD, Post CB. J Phys Chem B 116 4465-4475 (2012)
  150. Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase. Choi HJ, Smithgall TE. J Mol Biol 343 1255-1268 (2004)
  151. Deciphering the cross talk between hnRNP K and c-Src: the c-Src activation domain in hnRNP K is distinct from a second interaction site. Adolph D, Flach N, Mueller K, Ostareck DH, Ostareck-Lederer A. Mol Cell Biol 27 1758-1770 (2007)
  152. GPRC5B activates obesity-associated inflammatory signaling in adipocytes. Kim YJ, Sano T, Nabetani T, Asano Y, Hirabayashi Y. Sci Signal 5 ra85 (2012)
  153. O-GlcNAcylation is required for B cell homeostasis and antibody responses. Wu JL, Chiang MF, Hsu PH, Tsai DY, Hung KH, Wang YH, Angata T, Lin KI. Nat Commun 8 1854 (2017)
  154. Stress-evoked tyrosine phosphorylation of signal regulatory protein α regulates behavioral immobility in the forced swim test. Ohnishi H, Murata T, Kusakari S, Hayashi Y, Takao K, Maruyama T, Ago Y, Koda K, Jin FJ, Okawa K, Oldenborg PA, Okazawa H, Murata Y, Furuya N, Matsuda T, Miyakawa T, Matozaki T. J Neurosci 30 10472-10483 (2010)
  155. Adaptor protein Shc undergoes translocation and mediates up-regulation of the tyrosine kinase c-Src in EGF-stimulated A431 cells. Sato K, Kimoto M, Kakumoto M, Horiuchi D, Iwasaki T, Tokmakov AA, Fukami Y. Genes Cells 5 749-764 (2000)
  156. Encoding optical control in LCK kinase to quantitatively investigate its activity in live cells. Liaunardy-Jopeace A, Murton BL, Mahesh M, Chin JW, James JR. Nat Struct Mol Biol 24 1155-1163 (2017)
  157. Mapping of the auto-inhibitory interactions of protein kinase R by nuclear magnetic resonance. Gelev V, Aktas H, Marintchev A, Ito T, Frueh D, Hemond M, Rovnyak D, Debus M, Hyberts S, Usheva A, Halperin J, Wagner G. J Mol Biol 364 352-363 (2006)
  158. Reduced NMDA receptor tyrosine phosphorylation in PTPalpha-deficient mouse synaptosomes is accompanied by inhibition of four src family kinases and Pyk2: an upstream role for PTPalpha in NMDA receptor regulation. Le HT, Maksumova L, Wang J, Pallen CJ. J Neurochem 98 1798-1809 (2006)
  159. The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding. Chen S, Brier S, Smithgall TE, Engen JR. Protein Sci 16 572-581 (2007)
  160. Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1. Xiong X, Cui P, Hossain S, Xu R, Warner B, Guo X, An X, Debnath AK, Cowburn D, Kotula L. Biochim Biophys Acta 1783 737-747 (2008)
  161. Binding of bisubstrate analog promotes large structural changes in the unregulated catalytic trimer of aspartate transcarbamoylase: implications for allosteric regulation. Endrizzi JA, Beernink PT, Alber T, Schachman HK. Proc Natl Acad Sci U S A 97 5077-5082 (2000)
  162. Structural basis for autoinhibition of CTP:phosphocholine cytidylyltransferase (CCT), the regulatory enzyme in phosphatidylcholine synthesis, by its membrane-binding amphipathic helix. Lee J, Taneva SG, Holland BW, Tieleman DP, Cornell RB. J Biol Chem 289 1742-1755 (2014)
  163. The accessory factor Nef links HIV-1 to Tec/Btk kinases in an Src homology 3 domain-dependent manner. Tarafdar S, Poe JA, Smithgall TE. J Biol Chem 289 15718-15728 (2014)
  164. Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Brignatz C, Paronetto MP, Opi S, Cappellari M, Audebert S, Feuillet V, Bismuth G, Roche S, Arold ST, Sette C, Collette Y. Mol Cell Biol 29 6438-6448 (2009)
  165. Millisecond dynamics of BTK reveal kinome-wide conformational plasticity within the apo kinase domain. Sultan MM, Denny RA, Unwalla R, Lovering F, Pande VS. Sci Rep 7 15604 (2017)
  166. Modified AutoDock for accurate docking of protein kinase inhibitors. Buzko OV, Bishop AC, Shokat KM. J Comput Aided Mol Des 16 113-127 (2002)
  167. Nef alleles from all major HIV-1 clades activate Src-family kinases and enhance HIV-1 replication in an inhibitor-sensitive manner. Narute PS, Smithgall TE. PLoS One 7 e32561 (2012)
  168. Towards simple kinetic models of functional dynamics for a kinase subfamily. Sultan MM, Kiss G, Pande VS. Nat Chem 10 903-909 (2018)
  169. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Thaimattam R, Daga PR, Banerjee R, Iqbal J. Bioorg Med Chem 13 4704-4712 (2005)
  170. Comparison of binding energies of SrcSH2-phosphotyrosyl peptides with structure-based prediction using surface area based empirical parameterization. Henriques DA, Ladbury JE, Jackson RM. Protein Sci 9 1975-1985 (2000)
  171. Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis. Basu N, Bhandari R, Natarajan VT, Visweswariah SS. Mol Cell Biol 29 5277-5289 (2009)
  172. Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Kutach AK, Villaseñor AG, Lam D, Belunis C, Janson C, Lok S, Hong LN, Liu CM, Deval J, Novak TJ, Barnett JW, Chu W, Shaw D, Kuglstatter A. Chem Biol Drug Des 76 154-163 (2010)
  173. Effect of autophosphorylation on the catalytic and regulatory properties of protein tyrosine kinase Src. Sun G, Ramdas L, Wang W, Vinci J, McMurray J, Budde RJ. Arch Biochem Biophys 397 11-17 (2002)
  174. Stability of an autoinhibitory interface in the structure of the tyrosine kinase ZAP-70 impacts T cell receptor response. Deindl S, Kadlecek TA, Cao X, Kuriyan J, Weiss A. Proc Natl Acad Sci U S A 106 20699-20704 (2009)
  175. TGFβ1 rapidly activates Src through a non-canonical redox signaling mechanism. Zhang H, Davies KJ, Forman HJ. Arch Biochem Biophys 568 1-7 (2015)
  176. c-Src in paraventricular nucleus modulates sympathetic activity and cardiac sympathetic afferent reflex in renovascular hypertensive rats. Han Y, Yuan N, Zhang SJ, Gao J, Shi Z, Zhou YB, Gao XY, Zhu GQ. Pflugers Arch 461 437-446 (2011)
  177. Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Hossain S, Dubielecka PM, Sikorski AF, Birge RB, Kotula L. Genes Cancer 3 402-413 (2012)
  178. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis. Shekhtman A, Ghose R, Wang D, Cole PA, Cowburn D. J Mol Biol 314 129-138 (2001)
  179. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Schneeberger VE, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, Wu J. Carcinogenesis 35 1717-1725 (2014)
  180. The SH3 Domain Acts as a Scaffold for the N-Terminal Intrinsically Disordered Regions of c-Src. Maffei M, Arbesú M, Le Roux AL, Amata I, Roche S, Pons M. Structure 23 893-902 (2015)
  181. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, Ziaee N, Miller A, Jackson C, Fujimoto M, Young M, Batalov S, Liu Y, Warmuth M, Wiltshire T, Cooke MP, Sauer K. Mol Cell 33 43-52 (2009)
  182. Analysis of conformational changes during activation of protein kinase Pak2 by amide hydrogen/deuterium exchange. Hsu YH, Johnson DA, Traugh JA. J Biol Chem 283 36397-36405 (2008)
  183. Tyrosine 416 is phosphorylated in the closed, repressed conformation of c-Src. Irtegun S, Wood RJ, Ormsby AR, Mulhern TD, Hatters DM. PLoS One 8 e71035 (2013)
  184. Cooperative activation of Src family kinases by SH3 and SH2 ligands. Yadav SS, Miller WT. Cancer Lett 257 116-123 (2007)
  185. Lack of Csk-mediated negative regulation in a unicellular SRC kinase. Schultheiss KP, Suga H, Ruiz-Trillo I, Miller WT. Biochemistry 51 8267-8277 (2012)
  186. ROS-dependent activation of RhoA/Rho-kinase in pulmonary artery: Role of Src-family kinases and ARHGEF1. MacKay CE, Shaifta Y, Snetkov VV, Francois AA, Ward JPT, Knock GA. Free Radic Biol Med 110 316-331 (2017)
  187. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2. Malakhova M, Kurinov I, Liu K, Zheng D, D'Angelo I, Shim JH, Steinman V, Bode AM, Dong Z. PLoS One 4 e8044 (2009)
  188. p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck. Scholz G, Hartson SD, Cartledge K, Hall N, Shao J, Dunn AR, Matts RL. Mol Cell Biol 20 6984-6995 (2000)
  189. A case of X-linked agammaglobulinemia diagnosed in adulthood. Stewart DM, Tian L, Nelson DL. Clin Immunol 99 94-99 (2001)
  190. Dynamics of protein kinases: insights from nuclear magnetic resonance. Xiao Y, Liddle JC, Pardi A, Ahn NG. Acc Chem Res 48 1106-1114 (2015)
  191. ER-α36-mediated gastric cancer cell proliferation via the c-Src pathway. Wang X, Deng H, Zou F, Fu Z, Chen Y, Wang Z, Liu L. Oncol Lett 6 329-335 (2013)
  192. Src binds cortactin through an SH2 domain cystine-mediated linkage. Evans JV, Ammer AG, Jett JE, Bolcato CA, Breaux JC, Martin KH, Culp MV, Gannett PM, Weed SA. J Cell Sci 125 6185-6197 (2012)
  193. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Miyazawa K, Misawa K, Ohnota H, Isaji M. Bioorg Med Chem 16 7347-7357 (2008)
  194. A putative role for intramolecular regulatory mechanisms in the adaptor function of amphiphysin in endocytosis. Farsad K, Slepnev V, Ochoa G, Daniell L, Haucke V, De Camilli P. Neuropharmacology 45 787-796 (2003)
  195. Infectious Bursal Disease Virus Activates c-Src To Promote α4β1 Integrin-Dependent Viral Entry by Modulating the Downstream Akt-RhoA GTPase-Actin Rearrangement Cascade. Ye C, Han X, Yu Z, Zhang E, Wang L, Liu H. J Virol 91 e01891-16 (2017)
  196. M-CSF induces the stable interaction of cFms with alphaVbeta3 integrin in osteoclasts. Elsegood CL, Zhuo Y, Wesolowski GA, Hamilton JA, Rodan GA, Duong LT. Int J Biochem Cell Biol 38 1518-1529 (2006)
  197. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. Lee TS, Ma W, Zhang X, Kantarjian H, Albitar M. BMC Struct Biol 9 58 (2009)
  198. The tyrosine kinase Csk dimerizes through Its SH3 domain. Levinson NM, Visperas PR, Kuriyan J. PLoS One 4 e7683 (2009)
  199. The uric acid crystal receptor Clec12A potentiates type I interferon responses. Li K, Neumann K, Duhan V, Namineni S, Hansen AL, Wartewig T, Kurgyis Z, Holm CK, Heikenwalder M, Lang KS, Ruland J. Proc Natl Acad Sci U S A 116 18544-18549 (2019)
  200. A genetically encoded 19F NMR probe for tyrosine phosphorylation. Li F, Shi P, Li J, Yang F, Wang T, Zhang W, Gao F, Ding W, Li D, Li J, Xiong Y, Sun J, Gong W, Tian C, Wang J. Angew Chem Int Ed Engl 52 3958-3962 (2013)
  201. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM. Breast Cancer Res 10 R70 (2008)
  202. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. Salah E, Ugochukwu E, Barr AJ, von Delft F, Knapp S, Elkins JM. J Med Chem 54 2359-2367 (2011)
  203. Effect of protein kinase C and Ca(2+) on p42/p44 MAPK, Pyk2, and Src activation in rat conjunctival goblet cells. Hodges RR, Horikawa Y, Rios JD, Shatos MA, Dartt DA. Exp Eye Res 85 836-844 (2007)
  204. Herpes simplex virus requires VP11/12 to induce phosphorylation of the activation loop tyrosine (Y394) of the Src family kinase Lck in T lymphocytes. Wagner MJ, Smiley JR. J Virol 83 12452-12461 (2009)
  205. Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Hosoya N, Qiao Y, Hangaishi A, Wang L, Nannya Y, Sanada M, Kurokawa M, Chiba S, Hirai H, Ogawa S. Genes Chromosomes Cancer 42 269-279 (2005)
  206. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan SA, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL. Oncotarget 5 6038-6048 (2014)
  207. Role of PTPase(s) in regulating Fyn kinase at fertilization of the zebrafish egg. Wu W, Kinsey WH. Dev Biol 247 286-294 (2002)
  208. Screening for EphB signaling effectors using SILAC with a linear ion trap-orbitrap mass spectrometer. Zhang G, Fenyö D, Neubert TA. J Proteome Res 7 4715-4726 (2008)
  209. Temporal regulation of Lsp1 O-GlcNAcylation and phosphorylation during apoptosis of activated B cells. Wu JL, Wu HY, Tsai DY, Chiang MF, Chen YJ, Gao S, Lin CC, Lin CH, Khoo KH, Chen YJ, Lin KI. Nat Commun 7 12526 (2016)
  210. The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. Ishizawar RC, Tice DA, Karaoli T, Parsons SJ. J Biol Chem 279 23773-23781 (2004)
  211. p66shc inhibits insulin-like growth factor-I signaling via direct binding to Src through its polyproline and Src homology 2 domains, resulting in impairment of Src kinase activation. Xi G, Shen X, Clemmons DR. J Biol Chem 285 6937-6951 (2010)
  212. Clostridium difficile toxin A binds colonocyte Src causing dephosphorylation of focal adhesion kinase and paxillin. Kim H, Rhee SH, Pothoulakis C, LaMont JT. Exp Cell Res 315 3336-3344 (2009)
  213. Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Moro L, Simoneschi D, Kurz E, Arbini AA, Jang S, Guaragnella N, Giannattasio S, Wang W, Chen YA, Pires G, Dang A, Hernandez E, Kapur P, Mishra A, Tsirigos A, Miller G, Hsieh JT, Pagano M. Nat Cell Biol 22 1130-1142 (2020)
  214. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Verkhivker GM. Biopolymers 85 333-348 (2007)
  215. Regulation of Src trafficking and activation by the endocytic regulatory proteins MICAL-L1 and EHD1. Reinecke JB, Katafiasz D, Naslavsky N, Caplan S. J Cell Sci 127 1684-1698 (2014)
  216. Src family kinase tyrosine phosphorylates Toll-like receptor 4 to dissociate MyD88 and Mal/Tirap, suppressing LPS-induced inflammatory responses. Mitchell J, Kim SJ, Seelmann A, Veit B, Shepard B, Im E, Rhee SH. Biochem Pharmacol 147 119-127 (2018)
  217. Structural framework of c-Src activation by integrin β3. Xiao R, Xi XD, Chen Z, Chen SJ, Meng G. Blood 121 700-706 (2013)
  218. The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation. Shen K, Moroco JA, Patel RK, Shi H, Engen JR, Dorman HR, Smithgall TE. Sci Signal 11 eaat5916 (2018)
  219. Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N6 position. Hindley AD, Park S, Wang L, Shah K, Wang Y, Hu X, Shokat KM, Kolch W, Sedivy JM, Yeung KC. FEBS Lett 556 26-34 (2004)
  220. HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck. Pene-Dumitrescu T, Shu ST, Wales TE, Alvarado JJ, Shi H, Narute P, Moroco JA, Yeh JI, Engen JR, Smithgall TE. BMC Chem Biol 12 1 (2012)
  221. How Electrostatic Coupling Enables Conformational Plasticity in a Tyrosine Kinase. Tsai CC, Yue Z, Shen J. J Am Chem Soc 141 15092-15101 (2019)
  222. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency. Vihinen M, Villa A, Mella P, Schumacher RF, Savoldi G, O'Shea JJ, Candotti F, Notarangelo LD. Clin Immunol 96 108-118 (2000)
  223. Abl N-terminal cap stabilization of SH3 domain dynamics. Chen S, Dumitrescu TP, Smithgall TE, Engen JR. Biochemistry 47 5795-5803 (2008)
  224. Bombesin and angiotensin II rapidly stimulate Src phosphorylation at Tyr-418 in fibroblasts and intestinal epithelial cells through a PP2-insensitive pathway. Wu SS, Yamauchi K, Rozengurt E. Cell Signal 17 93-102 (2005)
  225. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues. Sundaramoorthi R, Shakespeare WC, Keenan TP, Metcalf CA, Wang Y, Mani U, Taylor M, Liu S, Bohacek RS, Narula SS, Dalgarno DC, van Schravandijk MR, Violette SM, Liou S, Adams S, Ram MK, Keats JA, Weigle M, Sawyer TK, Weigele M. Bioorg Med Chem Lett 13 3063-3066 (2003)
  226. CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation. Kwiatkowski B, Chen SY, Schubach WH. J Virol 78 6067-6072 (2004)
  227. Lateral hypothalamic signaling mechanisms underlying feeding stimulation: differential contributions of Src family tyrosine kinases to feeding triggered either by NMDA injection or by food deprivation. Khan AM, Cheung HH, Gillard ER, Palarca JA, Welsbie DS, Gurd JW, Stanley BG. J Neurosci 24 10603-10615 (2004)
  228. Modulation of the active complex assembly and turnover rate by protein-DNA interactions in Cre-LoxP recombination. Martin SS, Chu VC, Baldwin E. Biochemistry 42 6814-6826 (2003)
  229. Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2. Pisani P, Caporuscio F, Carlino L, Rastelli G. PLoS One 11 e0154066 (2016)
  230. T cell receptor signal initiation induced by low-grade stimulation requires the cooperation of LAT in human T cells. Dong S, Corre B, Nika K, Pellegrini S, Michel F. PLoS One 5 e15114 (2010)
  231. The Tec family kinase Itk exists as a folded monomer in vivo. Qi Q, August A. J Biol Chem 284 29882-29892 (2009)
  232. A Myristoyl-Binding Site in the SH3 Domain Modulates c-Src Membrane Anchoring. Le Roux AL, Mohammad IL, Mateos B, Arbesú M, Gairí M, Khan FA, Teixeira JMC, Pons M. iScience 12 194-203 (2019)
  233. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Nam NH, Lee S, Ye G, Sun G, Parang K. Bioorg Med Chem 12 5753-5766 (2004)
  234. Directly Activating the Integrin αIIbβ3 Initiates Outside-In Signaling by Causing αIIbβ3 Clustering. Fong KP, Zhu H, Span LM, Moore DT, Yoon K, Tamura R, Yin H, DeGrado WF, Bennett JS. J Biol Chem 291 11706-11716 (2016)
  235. Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans. Wang H, Liu B, Al-Aidaroos AQ, Shi H, Li L, Guo K, Li J, Tan BC, Loo JM, Tang JP, Thura M, Zeng Q. Oncogene 35 3303-3313 (2016)
  236. In silico investigation of potential SRC kinase ligands from traditional Chinese medicine. Tou WI, Chen CY. PLoS One 7 e33728 (2012)
  237. Inhibitory role of Src family tyrosine kinases on Ca2+-dependent insulin release. Cheng H, Straub SG, Sharp GW. Am J Physiol Endocrinol Metab 292 E845-52 (2007)
  238. Mechanistic studies of the mitotic activation of Mos. Yue J, Ferrell JE. Mol Cell Biol 26 5300-5309 (2006)
  239. Mutations in the catalytic loop HRD motif alter the activity and function of Drosophila Src64. Strong TC, Kaur G, Thomas JH. PLoS One 6 e28100 (2011)
  240. Src activation by Chk1 promotes actin patch formation and prevents chromatin bridge breakage in cytokinesis. Dandoulaki M, Petsalaki E, Sumpton D, Zanivan S, Zachos G. J Cell Biol 217 3071-3089 (2018)
  241. The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity. Laham LE, Mukhopadhyay N, Roberts TM. Oncogene 19 3961-3970 (2000)
  242. Yet another "active" pseudokinase, Erb3. Taylor SS, Kornev AP. Proc Natl Acad Sci U S A 107 8047-8048 (2010)
  243. Disordered linkers in multidomain allosteric proteins: Entropic effect to favor the open state or enhanced local concentration to favor the closed state? Li M, Cao H, Lai L, Liu Z. Protein Sci 27 1600-1610 (2018)
  244. Disrupting the intermolecular self-association of Itk enhances T cell signaling. Min L, Wu W, Joseph RE, Fulton DB, Berg L, Andreotti AH. J Immunol 184 4228-4235 (2010)
  245. SHPS-1 negatively regulates integrin alphaIIbbeta3 function through CD47 without disturbing FAK phosphorylation. Kato H, Honda S, Yoshida H, Kashiwagi H, Shiraga M, Honma N, Kurata Y, Tomiyama Y. J Thromb Haemost 3 763-774 (2005)
  246. Sensitive FRET Biosensor Reveals Fyn Kinase Regulation by Submembrane Localization. Ouyang M, Wan R, Qin Q, Peng Q, Wang P, Wu J, Allen M, Shi Y, Laub S, Deng L, Lu S, Wang Y. ACS Sens 4 76-86 (2019)
  247. Structure, dynamics, and binding thermodynamics of the v-Src SH2 domain: implications for drug design. Taylor JD, Ababou A, Fawaz RR, Hobbs CJ, Williams MA, Ladbury JE. Proteins 73 929-940 (2008)
  248. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. Kumar A, Wang Y, Lin X, Sun G, Parang K. ChemMedChem 2 1346-1360 (2007)
  249. The Usp8 deubiquitination enzyme is post-translationally modified by tyrosine and serine phosphorylation. Meijer IM, Kerperien J, Sotoca AM, van Zoelen EJ, van Leeuwen JE. Cell Signal 25 919-930 (2013)
  250. A conserved isoleucine maintains the inactive state of Bruton's tyrosine kinase. Boyken SE, Chopra N, Xie Q, Joseph RE, Wales TE, Fulton DB, Engen JR, Jernigan RL, Andreotti AH. J Mol Biol 426 3656-3669 (2014)
  251. Allosteric activation of proto-oncogene kinase Src by GPCR-beta-arrestin complexes. Pakharukova N, Masoudi A, Pani B, Staus DP, Lefkowitz RJ. J Biol Chem 295 16773-16784 (2020)
  252. An Autoinhibitory Role for the Pleckstrin Homology Domain of Interleukin-2-Inducible Tyrosine Kinase and Its Interplay with Canonical Phospholipid Recognition. Devkota S, Joseph RE, Boyken SE, Fulton DB, Andreotti AH. Biochemistry 56 2938-2949 (2017)
  253. Bioinformatic exploration of RIO protein kinases of parasitic and free-living nematodes. Breugelmans B, Jex AR, Korhonen PK, Mangiola S, Young ND, Sternberg PW, Boag PR, Hofmann A, Gasser RB. Int J Parasitol 44 827-836 (2014)
  254. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity. Verkhivker GM. Proteins 66 912-929 (2007)
  255. Evidence that phosphorylation of threonine in the GT motif triggers activation of PknA, a eukaryotic-type serine/threonine kinase from Mycobacterium tuberculosis. Ravala SK, Singh S, Yadav GS, Kumar S, Karthikeyan S, Chakraborti PK. FEBS J 282 1419-1431 (2015)
  256. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents. Tintori C, Laurenzana I, La Rocca F, Falchi F, Carraro F, Ruiz A, Esté JA, Kissova M, Crespan E, Maga G, Biava M, Brullo C, Schenone S, Botta M. ChemMedChem 8 1353-1360 (2013)
  257. Phage-display evolution of tyrosine kinases with altered nucleotide specificity. Ting AY, Witte K, Shah K, Kraybill B, Shokat KM, Schultz PG. Biopolymers 60 220-228 (2001)
  258. Roles for SH2 and SH3 domains in Lyn kinase association with activated FcepsilonRI in RBL mast cells revealed by patterned surface analysis. Hammond S, Wagenknecht-Wiesner A, Veatch SL, Holowka D, Baird B. J Struct Biol 168 161-167 (2009)
  259. The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion. Dölker N, Górna MW, Sutto L, Torralba AS, Superti-Furga G, Gervasio FL. PLoS Comput Biol 10 e1003863 (2014)
  260. An unexpected role for the clock protein timeless in developmental apoptosis. O'Reilly LP, Watkins SC, Smithgall TE. PLoS One 6 e17157 (2011)
  261. Coevolution of the domains of cytoplasmic tyrosine kinases. Nars M, Vihinen M. Mol Biol Evol 18 312-321 (2001)
  262. Computational study of the W260A activating mutant of Src tyrosine kinase. Meng Y, Roux B. Protein Sci 25 219-230 (2016)
  263. Controlling the activity of the Tec kinase Itk by mutation of the phenylalanine gatekeeper residue. Joseph RE, Andreotti AH. Biochemistry 50 221-229 (2011)
  264. Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Heim JB, Squirewell EJ, Neu A, Zocher G, Sominidi-Damodaran S, Wyles SP, Nikolova E, Behrendt N, Saunte DM, Lock-Andersen J, Gaonkar KS, Yan H, Sarkaria JN, Krendel M, van Deursen J, Sprangers R, Stehle T, Böttcher RT, Lee JH, Ordog T, Meves A. Proc Natl Acad Sci U S A 114 3933-3938 (2017)
  265. An auto-inhibitory helix in CTP:phosphocholine cytidylyltransferase hijacks the catalytic residue and constrains a pliable, domain-bridging helix pair. Ramezanpour M, Lee J, Taneva SG, Tieleman DP, Cornell RB. J Biol Chem 293 7070-7084 (2018)
  266. Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-induced c-Cbl-mediated ubiquitination in adherent human neutrophils. Melander F, Andersson T, Dib K. Biochem J 370 687-694 (2003)
  267. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. Francini CM, Fallacara AL, Artusi R, Mennuni L, Calgani A, Angelucci A, Schenone S, Botta M. ChemMedChem 10 2027-2041 (2015)
  268. Integrin-mediated tyrosine phosphorylation of Shc in T cells is regulated by protein kinase C-dependent phosphorylations of Lck. Niu S, Xie H, Marcantonio EE. Mol Biol Cell 14 349-360 (2003)
  269. KinCon: Cell-based recording of full-length kinase conformations. Enzler F, Tschaikner P, Schneider R, Stefan E. IUBMB Life 72 1168-1174 (2020)
  270. Regulation of Src and Csk nonreceptor tyrosine kinases in the filasterean Ministeria vibrans. Schultheiss KP, Craddock BP, Suga H, Miller WT. Biochemistry 53 1320-1329 (2014)
  271. The evolutionarily conserved arrangement of domains in SRC family kinases is important for substrate recognition. Yadav SS, Miller WT. Biochemistry 47 10871-10880 (2008)
  272. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors. Aronov AM, Bemis GW. Proteins 57 36-50 (2004)
  273. Autophosphorylation activates c-Src kinase through global structural rearrangements. Boczek EE, Luo Q, Dehling M, Röpke M, Mader SL, Seidl A, Kaila VRI, Buchner J. J Biol Chem 294 13186-13197 (2019)
  274. Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine. Advani G, Lim YC, Catimel B, Lio DSS, Ng NLY, Chüeh AC, Tran M, Anasir MI, Verkade H, Zhu HJ, Turk BE, Smithgall TE, Ang CS, Griffin M, Cheng HC. Cell Commun Signal 15 29 (2017)
  275. Divergent modulation of Rho-kinase and Ca(2+) influx pathways by Src family kinases and focal adhesion kinase in airway smooth muscle. Shaifta Y, Irechukwu N, Prieto-Lloret J, MacKay CE, Marchon KA, Ward JP, Knock GA. Br J Pharmacol 172 5265-5280 (2015)
  276. Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression. Wu W, Wang Y, Xu Y, Liu Y, Wang Y, Zhang H. Placenta 35 824-830 (2014)
  277. Porphyrins as new endogenous anti-inflammatory agents. Jelić D, Tatić I, Trzun M, Hrvačić B, Brajša K, Verbanac D, Tomašković M, Čulić O, Antolović R, Glojnarić I, Weygand-Đurašević I, Vladimir-Knežević S, Mildner B. Eur J Pharmacol 691 251-260 (2012)
  278. SRC family kinases and receptors: analysis of three activation mechanisms by dynamic systems modeling. Fuss H, Dubitzky W, Downes CS, Kurth MJ. Biophys J 94 1995-2006 (2008)
  279. Subtle Dynamic Changes Accompany Hck Activation by HIV-1 Nef and are Reversed by an Antiretroviral Kinase Inhibitor. Wales TE, Hochrein JM, Morgan CR, Emert-Sedlak LA, Smithgall TE, Engen JR. Biochemistry 54 6382-6391 (2015)
  280. Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib. Campos-Olivas R, Marenchino M, Scapozza L, Gervasio FL. Biomol NMR Assign 5 221-224 (2011)
  281. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. Hill ZB, Perera BG, Maly DJ. Mol Biosyst 7 447-456 (2011)
  282. Conformational States Control Lck Switching between Free and Confined Diffusion Modes in T Cells. Hilzenrat G, Pandžić E, Yang Z, Nieves DJ, Goyette J, Rossy J, Ma Y, Gaus K. Biophys J 118 1489-1501 (2020)
  283. GSTpi regulates VE-cadherin stabilization through promoting S-glutathionylation of Src. Yang Y, Dong X, Zheng S, Sun J, Ye J, Chen J, Fang Y, Zhao B, Yin Z, Cao P, Luo L. Redox Biol 30 101416 (2020)
  284. High-affinity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system. Mandine E, Jean-Baptiste V, Vayssière B, Gofflo D, Bénard D, Sarubbi E, Deprez P, Baron R, Superti-Furga G, Lesuisse D. Biochem Biophys Res Commun 298 185-192 (2002)
  285. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma. Musumeci F, Fallacara AL, Brullo C, Grossi G, Botta L, Calandro P, Chiariello M, Kissova M, Crespan E, Maga G, Schenone S. Eur J Med Chem 127 369-378 (2017)
  286. Reengineering the signaling properties of a Src family kinase. Yadav SS, Yeh BJ, Craddock BP, Lim WA, Miller WT. Biochemistry 48 10956-10962 (2009)
  287. SH3 domain of c-Src governs its dynamics at focal adhesions and the cell membrane. Machiyama H, Yamaguchi T, Sawada Y, Watanabe TM, Fujita H. FEBS J 282 4034-4055 (2015)
  288. The Structural Basis for Activation and Inhibition of ZAP-70 Kinase Domain. Huber RG, Fan H, Bond PJ. PLoS Comput Biol 11 e1004560 (2015)
  289. The crystal structure of the catalytic domain of the ser/thr kinase PknA from M. tuberculosis shows an Src-like autoinhibited conformation. Wagner T, Alexandre M, Duran R, Barilone N, Wehenkel A, Alzari PM, Bellinzoni M. Proteins 83 982-988 (2015)
  290. The saponin DT-13 attenuates tumor necrosis factor-α-induced vascular inflammation associated with Src/NF-кB/MAPK pathway modulation. Zhang Y, Sun M, Han Y, Zhai K, Tang Y, Qin X, Cao Z, Yu B, Kou J. Int J Biol Sci 11 970-981 (2015)
  291. 4-Hydroxynonenal activates Src through a non-canonical pathway that involves EGFR/PTP1B. Zhang H, Forman HJ. Free Radic Biol Med 89 701-707 (2015)
  292. Accurate prediction of interfacial residues in two-domain proteins using evolutionary information: implications for three-dimensional modeling. Bhaskara RM, Padhi A, Srinivasan N. Proteins 82 1219-1234 (2014)
  293. Automatic Selection of Order Parameters in the Analysis of Large Scale Molecular Dynamics Simulations. Sultan MM, Kiss G, Shukla D, Pande VS. J Chem Theory Comput 10 5217-5223 (2014)
  294. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. Fang L, Vilas-Boas J, Chakraborty S, Potter ZE, Register AC, Seeliger MA, Maly DJ. ACS Chem Biol 15 2005-2016 (2020)
  295. Neuromuscular synapse. Goodsell DS. Biochem Mol Biol Educ 37 204-210 (2009)
  296. Oxidation-Dependent Activation of Src Kinase Mediates Epithelial IL-33 Production and Signaling during Acute Airway Allergen Challenge. Dustin CM, Habibovic A, Hristova M, Schiffers C, Morris CR, Lin MJ, Bauer RA, Heppner DE, Daphtary N, Aliyeva M, van der Vliet A. J Immunol 206 2989-2999 (2021)
  297. Robust optimization of scoring functions for a target class. Seifert MH. J Comput Aided Mol Des 23 633-644 (2009)
  298. Tyrosine 192 within the SH2 domain of the Src-protein tyrosine kinase p56Lck regulates T-cell activation independently of Lck/CD45 interactions. Kästle M, Merten C, Hartig R, Kaehne T, Liaunardy-Jopeace A, Woessner NM, Schamel WW, James J, Minguet S, Simeoni L, Schraven B. Cell Commun Signal 18 183 (2020)
  299. Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. Kundrapu K, Colenberg L, Duhé RJ. Cell Biochem Biophys 52 103-112 (2008)
  300. Activation of RSK by phosphomimetic substitution in the activation loop is prevented by structural constraints. Somale D, Di Nardo G, di Blasio L, Puliafito A, Vara-Messler M, Chiaverina G, Palmiero M, Monica V, Gilardi G, Primo L, Gagliardi PA. Sci Rep 10 591 (2020)
  301. Hypothermia-induced tyrosine phosphorylation of SIRPα in the brain. Maruyama T, Kusakari S, Sato-Hashimoto M, Hayashi Y, Kotani T, Murata Y, Okazawa H, Oldenborg PA, Kishi S, Matozaki T, Ohnishi H. J Neurochem 121 891-902 (2012)
  302. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib. Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X. Clin Sci (Lond) 122 13-24 (2012)
  303. Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain. Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer CA, Spassov DS, Oses-Prieto J, Burlingame A, Moasser MM. Mol Cancer Res 19 957-967 (2021)
  304. Regulation of the firing activity by PKA-PKC-Src family kinases in cultured neurons of hypothalamic arcuate nucleus. Sun XD, Wang A, Ma P, Gong S, Tao J, Yu XM, Jiang X. J Neurosci Res 98 384-403 (2020)
  305. Src signaling in a low-complexity unicellular kinome. Suga H, Miller WT. Sci Rep 8 5362 (2018)
  306. Structural Characterization of Maize SIRK1 Kinase Domain Reveals an Unusual Architecture of the Activation Segment. Aquino B, Couñago RM, Verza N, Ferreira LM, Massirer KB, Gileadi O, Arruda P. Front Plant Sci 8 852 (2017)
  307. The exon 7-spliced Lck isoform in T lymphocytes: a potential regulator of p56lck signaling pathways. Germani A, Malherbe S, Rouer E. Biochem Biophys Res Commun 301 680-685 (2003)
  308. Theoretical studies of the role of C-terminal cysteines in the process of S-nitrosylation of human Src kinases. Andre FR, dos Santos PF, Rando DG. J Mol Model 22 23 (2016)
  309. A Model for the Signal Initiation Complex Between Arrestin-3 and the Src Family Kinase Fgr. Perez I, Berndt S, Agarwal R, Castro MA, Vishnivetskiy SA, Smith JC, Sanders CR, Gurevich VV, Iverson TM. J Mol Biol 434 167400 (2022)
  310. Discovery of Non-peptide Small Molecule Allosteric Modulators of the Src-family Kinase, Hck. Dorman HR, Close D, Wingert BM, Camacho CJ, Johnston PA, Smithgall TE. Front Chem 7 822 (2019)
  311. Evolution of Functional Diversity in the Holozoan Tyrosine Kinome. Yeung W, Kwon A, Taujale R, Bunn C, Venkat A, Kannan N. Mol Biol Evol 38 5625-5639 (2021)
  312. Inhibition of a signaling modality within the gp130 receptor enhances tissue regeneration and mitigates osteoarthritis. Shkhyan R, Flynn C, Lamoure E, Sarkar A, Van Handel B, Li J, York J, Banks N, Van der Horst R, Liu NQ, Lee S, Bajaj P, Vadivel K, Harn HI, Tassey J, Lozito T, Lieberman JR, Chuong CM, Hurtig MS, Evseenko D. Sci Transl Med 15 eabq2395 (2023)
  313. Involvement of the SH3 domain in Ca2+-mediated regulation of Src family kinases. Monteiro AN. Biochimie 88 905-911 (2006)
  314. Spectroscopic characterization of the SH2- and active site-directed peptide sequences of a bivalent Src kinase inhibitor. Desamero RZ, Kang J, Dol C, Chinwong J, Walters K, Sivarajah T, Profit AA. Appl Spectrosc 63 767-774 (2009)
  315. Src Family Kinases Facilitate the Crosstalk between CGRP and Cytokines in Sensitizing Trigeminal Ganglion via Transmitting CGRP Receptor/PKA Pathway. Nie L, Sun K, Gong Z, Li H, Quinn JP, Wang M. Cells 11 3498 (2022)
  316. gp130 Cytokines Activate Novel Signaling Pathways and Alter Bone Dissemination in ER+ Breast Cancer Cells. Omokehinde T, Jotte A, Johnson RW. J Bone Miner Res 37 185-201 (2022)
  317. A Companion Guide to the String Method with Swarms of Trajectories: Characterization, Performance, and Pitfalls. Chen H, Ogden D, Pant S, Cai W, Tajkhorshid E, Moradi M, Roux B, Chipot C. J Chem Theory Comput 18 1406-1422 (2022)
  318. Allosteric regulation of autoinhibition and activation of c-Abl. Liu Y, Zhang M, Tsai CJ, Jang H, Nussinov R. Comput Struct Biotechnol J 20 4257-4270 (2022)
  319. Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells. Shaffer JM, Hellwig S, Smithgall TE. Biochemistry 48 4780-4788 (2009)
  320. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques. Ramakrishnan C, Mary Thangakani A, Velmurugan D, Anantha Krishnan D, Sekijima M, Akiyama Y, Gromiha MM. J Biomol Struct Dyn 36 1566-1576 (2018)
  321. Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines. Valle-Mendiola A, Bustos-Rodríguez R, Domínguez-Melendez V, Zerecero-Carreón O, Gutiérrez-Hoya A, Weiss-Steider B, Soto-Cruz I. Oncol Lett 23 71 (2022)
  322. Nonphosphorylatable Src Ser75 Mutation Increases Ethanol Preference and Consumption in Mice. Kato G. eNeuro 6 ENEURO.0418-18.2019 (2019)
  323. Phosphotyrosine signalling and the origin of animal multicellularity. Tong K, Wang Y, Su Z. Proc Biol Sci 284 20170681 (2017)
  324. The MAF1 Phosphoregulatory Region Controls MAF1 Interaction with the RNA Polymerase III C34 Subunit and Transcriptional Repression in Plants. Oliveira Andrade M, Sforça ML, Batista FAH, Figueira ACM, Benedetti CE. Plant Cell 32 3019-3035 (2020)
  325. In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-Family Kinase C-Helix-out Inhibitor Resistance. Patel RK, Patel YK, Smithgall TE. ACS Chem Biol 15 2175-2184 (2020)
  326. Activation Loop Plasticity and Active Site Coupling in the MAP Kinase, ERK2. Pegram L, Riccardi D, Ahn N. J Mol Biol 435 168309 (2023)
  327. Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase. Berndt S, Gurevich VV, Iverson TM. PLoS One 14 e0215140 (2019)
  328. Crystal structures of the kinase domain of PpkA, a key regulatory component of T6SS, reveal a general inhibitory mechanism. Li P, Xu D, Ma T, Wang D, Li W, He J, Ran T, Wang W. Biochem J 475 2209-2224 (2018)
  329. Effect of the SH3-SH2 domain linker sequence on the structure of Hck kinase. Meiselbach H, Sticht H. J Mol Model 17 1927-1934 (2011)
  330. Intrinsic properties and plasma membrane trafficking route of Src family kinase SH4 domains sensitive to retargeting by HIV-1 Nef. Chase AJ, Wombacher R, Fackler OT. J Biol Chem 293 7824-7840 (2018)
  331. Mapping protein pockets through their potential small-molecule binding volumes: QSCD applied to biological protein structures. Mason K, Patel NM, Ledel A, Moallemi CC, Wintner EA. J Comput Aided Mol Des 18 55-70 (2004)
  332. Molecular determinants of Hsp90 dependence of Src kinase revealed by deep mutational scanning. Nguyen V, Ahler E, Sitko KA, Stephany JJ, Maly DJ, Fowler DM. Protein Sci 32 e4656 (2023)
  333. Oxidative stress promotes fibrosis in systemic sclerosis through stabilization of a kinase-phosphatase complex. Zhang R, Kumar GS, Hansen U, Zoccheddu M, Sacchetti C, Holmes ZJ, Lee MC, Beckmann D, Wen Y, Mikulski Z, Yang S, Santelli E, Page R, Boin F, Peti W, Bottini N. JCI Insight 7 e155761 (2022)
  334. Regulation of expression and function of Lck tyrosine kinase by high cell density. Ozegbe P, Chernajovsky Y, Kabouridis PS. Mol Membr Biol 22 363-372 (2005)
  335. Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. Guerin N, Feichtner A, Stefan E, Kaserer T, Donald BR. Cell Syst 13 830-843.e3 (2022)
  336. Structural basis for the activity of pp60(c-src) protein tyrosine kinase inhibitors. Prabhu NV, Siddiqui SA, McMurray JS, Pettitt BM. Biopolymers 59 167-179 (2001)
  337. Structure and function of Tec family kinase Itk. Qi Q, Kannan AK, August A. Biomol Concepts 2 223-232 (2011)
  338. The molecular perspective: the Src oncogene. Goodsell DS. Stem Cells 19 553-555 (2001)
  339. Theoretical Insights Reveal Novel Motions in Csk's SH3 Domain That Control Kinase Activation. Barkho S, Pierce LC, Li S, Adams JA, Jennings PA. PLoS One 10 e0127724 (2015)
  340. Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer. Zou H, Luo J, Guo Y, Tong T, Liu Y, Chen Y, Xiao Y, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P. Cell Mol Life Sci 80 41 (2023)
  341. A rapid ATP affinity-based purification for the human non-receptor tyrosine kinase c-Src. Jeansonne DP, Bordes TJ, Bennett CA, Kothandaraman G, Bush JG, Vaccaro JA. Protein Expr Purif 46 240-247 (2006)
  342. Chemical shift assignments of the partially deuterated Fyn SH2-SH3 domain. Kieken F, Loth K, van Nuland N, Tompa P, Lenaerts T. Biomol NMR Assign 12 117-122 (2018)
  343. Combined Immunodeficiency Caused by a Novel Nonsense Mutation in LCK. Keller B, Kfir-Erenfeld S, Matusewicz P, Hartl F, Lev A, Lee YN, Simon AJ, Stauber T, Elpeleg O, Somech R, Stepensky P, Minguet S, Schraven B, Warnatz K. J Clin Immunol 44 4 (2023)
  344. Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Dave Z, Vondálová Blanářová O, Čada Š, Janovská P, Zezula N, Běhal M, Hanáková K, Ganji SR, Krejci P, Gömöryová K, Peschelová H, Šmída M, Zdráhal Z, Pavlová Š, Kotašková J, Pospíšilová Š, Bryja V. Front Cell Dev Biol 10 838871 (2022)
  345. Modulation of Functional Phosphorylation Sites by Basic Residues in the Unique Domain of c-Src. Lang A, Fernández A, Diaz-Lobo M, Vilanova M, Cárdenas F, Gairí M, Pons M. Molecules 28 4686 (2023)
  346. Molecular Simulations of Conformational Transitions within the Insulin Receptor Kinase Reveal Consensus Features in a Multistep Activation Pathway. Nam K, Tao Y, Ovchinnikov V. J Phys Chem B 127 5789-5798 (2023)
  347. Phosphorylation of tyrosine 90 in SH3 domain is a new regulatory switch controlling Src kinase. Koudelková L, Pelantová M, Brůhová Z, Sztacho M, Pavlík V, Pánek D, Gemperle J, Talacko P, Brábek J, Rösel D. Elife 12 e82428 (2023)
  348. Structural versatility that serves the function of the HRD motif in the catalytic loop of protein tyrosine kinase, Src. Cui Y, Sun G. Protein Sci 28 533-542 (2019)


Quick links